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Summary 
Human Vγ9Vδ2 T cells are the major subset of blood γδ T cells and account for 1-5% of 
blood T cells. Pyrophosphorylated metabolites of isoprenoid biosynthesis are recognized by 
human Vγ9Vδ2 T cells and are called as phosphoantigens (PAg). Isopentenyl pyrophosphate 
(IPP) and (E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) are among the few well 
studied PAg. IPP is found in all organisms while HMBPP is a precursor of IPP found only in 
eubacteria, plants and apicomplexaen parasite.  Interestingly, the PAg reactive Vγ9Vδ2 T 
cells are so far identified only in human and higher primates but not in rodents. Hence, 
Vγ9Vδ2 T cells are believed to be restricted to primates. With regard to PAg recognition, a 
Vγ9JP recombined TCRγ chain and certain CDR3 motifs of the TCR chain are mandatory.  
The BTN3A1 molecule is essential for a response to PAg. BTN3 is a trans-membrane protein 
belonging to butyrophilin family of proteins. Though BTN3A1 was found to be essential for 
PAg presentation, the exact molecular basis of PAg presentation still remains unclear.  
This thesis presents new data on the evolution of Vγ9Vδ2 TCR and its ligands (BTN3) as 
well as the genetic basis of PAg presentation to Vγ9Vδ2 TCR.  
The comprehensive analysis of genomic database sequences at NCBI and other public 
domain databases revealed for the first time that Vγ9, Vδ2 and BTN3 genes emerged and co-
evolved along with the placental mammals. Vγ9, Vδ2 and BTN3 genes are scattered across 
mammalian species and not restricted to primates. But interestingly, all three genes are highly 
conserved between phylogenetically distinct species. Moreover, the distribution pattern of 
Vγ9, Vδ2 TCR genes and BTN3 genes suggests a functional association between these genes 
representing the TCR - ligand relationship. Alpaca (Vicugna pacos), a member of the camelid 
family, is one among the 6 candidate non-primate species which were found to possess 
functional Vγ9, Vδ2 and BTN3 genes.  
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From peripheral lymphocytes of alpaca, Vγ9 chain transcripts with a characteristic JP 
rearrangement and transcripts of Vδ2 chains with a CDR3 typical for PAg-reactive TCR were 
identified. The transduction of αβ TCR negative mouse thymoma BW cells with alpaca Vγ9 
and Vδ2 TCR chains resulted in surface expression of the TCR complex as it was deduced 
from detection of cell surface expression of mouse CD3. Cross-linking of alpaca Vγ9Vδ2 
TCR transductants with anti-CD3ε led to IL-2 production which confirmed that alpaca Vγ9 
and Vδ2 TCR chains pair to form a functional TCR. Besides the conservation of human like 
Vγ9 and Vδ2 TCR chains, alpaca has conserved an orthologue for human BTN33A1 as well. 
Interestingly, the predicted PAg binding sites of human BTN3A1 was 100% conserved in 
deduced amino acid sequence of alpaca BTN3A1. All together alpaca is a promising 
candidate for further studies as it might have preserved Vγ9Vδ2 T cells to function in 
surveillance of stress and infections. 
This thesis also provides the sequence of Vγ9Vδ2 TCR of African green monkey 
(Chlorocebus aethiops), which was previously unknown. Moreover, our data indicates the 
lack of any species specific barrier which could hinder the PAg presentation by African 
monkey derived COS cells to human Vγ9Vδ2 TCR and vice versa of human cells to African 
green monkey Vγ9Vδ2 TCR which was in contradiction to previously reported findings. 
Apart from the above, the thesis also presents new data on the genetic basis of PAg 
presentation to Vγ9Vδ2 T cells, which revealed that human chromosome 6 is sufficient for 
the presentation of exogenous and endogenous PAg. By employing human/mouse somatic 
hybrids, we identified the role of human chromosome 6 in PAg presentation and in addition, 
we observed the lack of capacity of human chromosome 6 positive hybrids to activate 
Vγ9Vδ2 TCR transductants in the presence of the alkylamine sec-butylamine (SBA). 
Investigation of Chinese hamster ovary (CHO) cells containing the human chromosome 6 
also yielded similar results. This suggests that aminobisphosphonates (zoledronate) and 
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alkylamines employ different mechanisms for activation of Vγ9Vδ2 T cells although both 
have been described to act by inhibition of farnesyl pyrophosphate synthase activity which is 
known to increase intracellular levels of the IPP. 
In conclusion, this thesis suggests that Vγ9, Vδ2 and BTN3 genes controlling Vγ9Vδ2 TCR- 
ligand relationship emerged and co-evolved along with placental mammals; and also 
identified candidate non-primate species which could possess Vγ9Vδ2 T cells. Furthermore, 
it suggests alpaca as a promising non-primate species to investigate the physiological 
function of Vγ9Vδ2 T cells. With respect to PAg antigen presentation it was shown that 
chromosome 6 is essential and sufficient for exogenous and endogenous PAg presentation. 
Moreover, the alkylamine SBA and aminobisphosphonate zoledronate may engage different 
cellular mechanism to exert inhibition over IPP consumption. The thesis raises interesting 
questions which need to be addressed in future: 1) What are the environmental and 
evolutionary factors involved in preservation of Vγ9Vδ2 T cells only by few species? 2) 
What could be the functional nature and antigen recognition properties of such a conserved T 
cell subset? 3) What is the genetic and molecular basis of the differential capacity of human 
chromosome 6 bearing rodent-human hybridoma cells in activating Vγ9Vδ2 T cells in 
presence of SBA and aminobisphosphonates? 
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Zusammenfassung 
Vγ9Vδ2 T Zellen stellen im Menschen die größte Population an γδ T Zellen im Blut dar. Ihr 
Anteil an den Blut-T Zellen beträgt 1-5%. Humane Vγ9Vδ2 T Zellen erkennen als 
Phosphoantigene (PAg) bezeichnete pyrophosphorylierte Metabolite der 
Isoprenoidbiosynthese wobei Isopentenylpyrophosphat (IPP) und (E)-4-Hydroxy-3-methyl-
but-2-enylpyrophosphat (HMBPP) zu den wenigen gut erforschten PAg gehören. IPP ist in 
allen Organismen zu finden während HMBPP ein IPP Vorläufer ist, der nur in Eubakterien, 
Pflanzen und Apikomplexa vorkommt. Interessanterweise wurden PAg-reaktive Vγ9Vδ2 T 
Zellen bisher nur im Menschen und höheren Primaten gefunden, aber nicht in Nagern. Daher 
wurde angenommen, dass Vγ9Vδ2 T Zellen eine exklusiv in Primaten vorkommende 
Population darstellt. Hinsichtlich der PAg-Bindung sind TCR  Ketten  mit einer 
Rekombination von Vγ9 und JP zwingend notwendig und bestimmte CDR3 Motive der V2 
TCR Kette, wobei die Erkennung der PAg von der Präsenz des BTN3A1 Moleküls abhängt. 
BTN3 ist ein Transmembranprotein und gehört zur Butyrophilinfamilie. Obwohl gezeigt 
wurde, das BTN3A für die PAg-Präsentierung unerlässlich ist, ist deren molekularer 
Mechanismus noch immer unklar.  
Die vorgelegte Arbeit beinhaltet sowohl neue Daten über die Evolution des Vγ9Vδ2 TCR 
und dessen Liganden (BTN3), als auch über die genetischen Grundlagen der PAg-
Präsentierung. 
Eine umfassende Analyse genomischer Datenbanksequenzen des NCBI sowie anderer 
öffentlicher Datenbanken zeigte erstmals, dass Vγ9, Vδ2 und BTN3 Gene zusammen mit den 
höheren Säugetieren (Placentalia) entstanden und sich gemeinsam weiter entwickelten. Vγ9, 
Vδ2 und BTN3 Gene existieren über die gesamten Placentalia verteilt und nicht allein in 
Primaten. Erstaunlicherweise sind alle drei Gene auch zwischen phylogenetisch 
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unterschiedlichen Spezies hoch konserviert und das Verteilungsmuster von Vγ9, Vδ2 und 
BTN3 Genen lässt auf eine funktionale Verbindung dieser Gene schliessen, wie sie die 
TCR/Ligand Interaktion darstellt. Weitergehende Analysen resultierten in der Identifizierung 
von sechs möglichen Kandidatenspezies, die nicht zu den Primaten gehören und funktionelle 
Vγ9, Vδ2 und BTN3 Gene besitzen. Hierzu gehört auch das Alpaka (Vicugna pacos), ein 
Mitglied der Famile der Kamele. 
Aus periphären Alpakalymphozyten wurden TCR-γ-Kettentranskripte mit charakteristischem 
Vγ9JP Rearrangement sowie TCR-δ-Kettentranskripte mit für PAg-reaktive Zellen typischen 
CDR3 amplifiziert. Die Transduktion der Alpaka-Vγ9 und Vδ2 Ketten in die TCR-negativen 
Maus T-Zell Hybridomlinie BW resultierte in einer Oberflächenexpression des TCR 
Komplex wie aus der Zelloberflächenexpression von Maus CD3 geschlossen werde konnte. 
Die Aktivierung dieses TCR Komplexes mittels anti-CD3ε Antikörpern führte zur Produktion 
von IL-2 durch die TCR-Transduktante, was die funktionelle Paarung der Alpaka Vγ9 und 
Vδ2 TCR-Ketten bestätigte. Neben den Vγ9 und Vδ2 TCR-Kettengenen existiert im 
Alpakagenom ebenso ein konserviertes Ortholog des humanen BTN3. Interessanterweise sind 
die mutmaßlichen PAg-Bindungsstellen des humanen BTN3A1 in dessen abgeleiteter 
Aminosäuresequenz zu 100% konserviert. Diese Daten machen  das Alpaka zu einen 
vielversprechenden Kandidaten für weitere Untersuchungen, da hier möglicherweise die 
Population der Vγ9Vδ2 Zellen in ihrer Funktion zur Überwachung von Stress und 
Infektionen erhalten geblieben ist. 
Ebenso liefert diese Arbeit die Sequenz des Vγ9Vδ2 TCR der Grünen Meerkatze 
(Chlorocebus aethiops), welche zuvor nicht bekannt war. Darüber hinaus wurde keine 
Speziesspezifität in der Präsentierung von PAg durch COS Zellen der Grünen Meerkatze für 
den humanen Vγ9Vδ2 TCR oder umgekehrt der Präsentierung von PAg durch 
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Meerkatzenzellen für humane Vγ9Vδ2 TCRs gefunden, was im im Widerspruch zu bisher 
veröffentlichten Ergebnissen steht. 
Zudem liefert diese Arbeit auch neue Ergebnisse zur genetischen Grundlage der PAg- 
Präsentierung für die Vγ9Vδ2 T Zellen. Hier zeigte sich, dass das humane Chromosom 6 für 
die Präsentierung exogener sowie endogener PAg ausreicht. Durch die Generierung 
somatischer Mensch/Maus Hybride konnten wir die Rolle des humanen Chromosom 6 in der 
Phosphoantigenpräsentierung ermitteln und zudem beobachten, dass Chromosom 6 positive 
Hybride nicht in der Lage waren, Vγ9Vδ2 TCR Transduktanten in Anwesenheit des 
Alkylamins sec-Butylamin (SBA) zu aktivieren. Desweiteren brachten Versuche mit 
Ovarialzellen des chinesischen Hamsters (CHO), die das humane Chromosom 6 enthielten, 
ähnliche Ergebnisse. Dies legt nahe, dass Aminobisphosphonate (Zoledronat) und 
Alkylamine unterschiedliche Mechanismen der Aktivierung von Vγ9Vδ2 T Zellen nutzen 
obwohl für beide beschrieben ist, dass sie durch Inhibition der Farnesylpyrophosphatsynthase 
wirken, die wiederum zum Anstieg des intrazellulären IPP-Spiegels führt. 
Zusammengefasst legt diese Arbeit die Co-Evolution der die Vγ9Vδ2 TCR/Ligand 
Interaktion kontrollierenden Vγ9, Vδ2 und BTN3 Gene in Placentalia nahe und identifiziert 
nicht den Primaten zugehörige Spezies als Kandidaten, die Vγ9Vδ2T Zellen besitzen 
könnten, von denen das Alpaka als vielversprechend für die Untersuchung der 
physiologischen Rolle von Vγ9Vδ2 T Zellen vorgeschlagen wird. Hinsichtlich der PAg-
Präsentierung bestätigen die vorliegenden Ergebnisse, dass das humane Chromosom 6 
zugleich nötig und ausreichend ist, endogene sowie exogene PAg zu präsentieren. Zudem 
könnten das Alkylamin SBA und Aminobiosphonat Zoledronat verschiedene Mechanismen 
zur Inhibierung des IPP Verbrauchs nutzen. Diese Ergebnisse werfen einige Fragen auf, die 
es in Zukunft zu beantworten gilt: 1) Was sind die Umwelt- und Evolutionsfaktoren, die dazu 
geführt haben, dass Vγ9Vδ2 T Zellen nur in wenigen Spezies erhalten blieben? 2) Was 
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könnte die funktionale Natur und die Antigenbindungseigenschaften einer solchen 
konservierten T Zell Population sein? 3) Was ist die genetische und molekulare Grundlage 
für die unterschiedliche Fähigkeit von das humane Chromosom 6 tragenden Mensch-Nager 
Hybridomazellen, Vγ9Vδ2 T Zellen in Anwesenheit von SBA und Aminobisphosphonaten zu 
aktivieren?   
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1. Introduction 
Jawed vertebrates (Gnathostomata) have evolved an adaptive immune system in addition to 
innate immune system to combat pathogens (1). The cell types of the hallmark adaptive 
immune system of jawed vertebrates are lymphocytes, which by their characteristic three 
antigen receptors can be divided into three cell lineages, namely γδ T cells, αβ T cells and B 
cells. These receptors have been conserved for 400-500 million years (2, 3). Unlike αβ T 
cells, γδ T cells are MHC independent in antigen recognition. γδ T cells are different from 
conventional αβ T cells in several aspects, especially with regard to co-receptors. Most of the 
γδ T cells are negative for CD4 or CD8 which act as co-receptors for MHC class II and MHC 
class I molecules, respectively (4). Lack of co-receptors by γδ T cells is in line with the MHC 
independent antigen recognition and response (5).  
 
1.1 Evolution of antigen receptors in jawed vertebrates 
T cell receptors (TCR) and immunoglobulins (Ig) are the two major classes of antigen 
recognition receptors of jawed vertebrates (6). TCR and Ig belong to a large protein family 
called immunoglobulin super family (IGSF) and they are more closely related to each other 
than rest of the family members (7). Both TCR and Ig are generated by a process called 
somatic recombination where variable (V), diversity (D) and joining (J) gene segments 
become rearranged in a process called somatic recombination or rearrangement, which is 
guided by the products of recombination-activating genes (RAG1 and RAG2) (Fig 1) (8). 
This process is critical for the generation of T- and B-lymphocytes and occurs in the primary 
lymphatic organs. Furthermore, immunoglobulins attain another quality of diversity through 
somatic hypermutation (SHM), where V regions of B cell receptor are subjected to undergo 
mutations to achieve high-affinity antigen binding sites. This process occurs during the 
Introduction 
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immune response in secondary lymphatic organs and is restricted to B cell receptors but is 
not found in (MHC-restricted) T-cells. (9).  
 
 
Figure 1: VDJ recombination of lymphocytes antigen receptors 
During VDJ recombination, the recombination activation gene (RAG1-RAG2) recognizes the recombination 
signal sequences (Red and blue triangles) of individual gene segments (red and blue genes). Upon recognition, 
enzymes introduces two double stranded breaks with blunt end and introduces hair-pin loop to the desired 
coding sequence ends. During the joining of desired coding sequences, terminal deoxytransferase induces 
random nucleotide sequences (tiny yellow box) which dramatically raise the diversity of the repertoire. 
Simultaneously, RSS sequences were joined and excision of the undesired V genes as circles takes place. In this 
manner V gene (Red box), D gene (green box) and J gene (Blue box) sequences were recombined. The above 
picture was adapted from a review (6). 
 
Immunoglobulins occur as membrane bound B-cell antigen-receptors (BCR) as well as 
secreted molecules (antibodies). They recognize antigens directly without the need of antigen 
presenting cells or molecules (10). In contrast to Ig, there are no soluble forms of TCR. The 
conventional αβ TCRs are restricted to recognition of MHC-bound peptides (11). 
Interestingly, γδ TCRs recognizes both membrane bound antigens as well soluble antigens, 
which is similar to immunoglobulins (5, 12-14). Additionally, γδ TCRs carry specificities for 
the recognition of ligands and presenting molecules, similar to αβ TCRs (15). Also studies 
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have shown that antigen recognition of γδ TCR is to an extent similar to immunoglobulins 
(16). Since γδ TCRs possess structural properties and antigen recognition properties, which 
are shared by αβ TCRs and immunoglobulins, it has been proposed that all three antigen 
receptor structures might have arose from a γδ TCR-like antigen recognition receptor (6, 10) 
 
1.2 Gamma and delta antigen receptor genes 
Every TCR chain is assembled by splicing of primary transcript composed of VJ or VDJ 
recombined gene segments and C segments. The γ-chain genes are assembled via VJ 
rearrangement whereas the δ-chain genes are by V-D-J rearrangement and it commonly 
involves multiple D segments (Fig 2). There are some unique properties of generic γδ TCR 
which act like γδ signatures, such as presence of serine residue at position 8 and a IHWY 
motif at positions 34-37 of Vγ gene (17-19). Interestingly, Vγ gene always carries a 
negatively charged residue at position 37 whereas Vδ gene carries a positively charged 
residue. This feature may enable them to have a unique γ/δ chain pairing. Compared to Vα 
segments, CDR1 or CDR2 of Vδ and Vγ genes are longer which can restrict pairing of Vδ 
chain to specific Vγ chain. For example, human Vγ9 and Vδ2 have CDR1 which have two 
extra amino acids, whereas Vγ1.3 and Vδ3 share similar feature in CDR2. Sharing such 
features predicts the restricted pairing, which proves to be a nature of γδ TCR (20). With 
regard to CDR3 regions, CDR3δ are highly diverse similar to IgH CDR3s (14) but CDR3δ 
differs from conventional αβ TCR chain by D-D joining segments and flexibility in reading 
frame usage. This feature yields higher diversity and variability in CDR3δ lengths and so the 
length of CDR3δ ranges from 8-21 amino acids (14, 21). This may also enable them to 
recognize diverse antigens. Whereas Vγ CDR3 regions are not as long as Vδ, but they too 
show a high degree of variability in length (1-12 amino acids) (14).  
Introduction 
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Figure 2: Human TCR gamma delta locus 
Human TCR gamma locus lies on chromosome 7 and TCR delta locus lies on chromosome 14. Green oval 
shaped box indicates functional Vγ and Vδ genes. Red oval boxed indicate pseudo Vγ genes (adapted from 
(22)). 
 
Though jawed vertebrates have three cell lineages bearing antigen receptor, Ig and TCR V 
genes can be classified into families sharing 75% identity. Among the TCR V genes, Vα/β/δ 
confers high similarity between different species for example human and mice, which is not 
so in the case of Vγ genes (19). Vγ genes have shown remarkable divergence between 
phylogenetically related and unrelated species. Secondly, Vγ genes show high divergence 
with respect to genetic complexity. In species like human and mice, they appeared to have 
only 6 functional Vγ genes whereas in chicken, there are as plenty as 20-30 genes (23). 
Interestingly, γδ T cells exhibit direct correlation between abundance of γδ T cells and their 
genetic complexity. Species with fewer Vγ and Vδ genes have fewer γδ cells in periphery 
(<5% in human and mice) but they are abundant in chicken as well as in the peripheral blood 
(>70%) of ruminants (24, 25). Another interesting feature of γδ T cells is the remarkable 
correlation between the usage of TCR genes and their anatomical localization (26). 
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1.3 Human γδ T cells 
Vγ genes are more diverse than other TCR V genes, which is well illustrated by the presence 
of unique Vγ genes in mouse and human (19). Several unique γδ T cell subsets which possess 
diverse and unique antigen recognition properties such as Vγ9Vδ2 T cells were identified in 
humans. In the past two decades, human γδ T cells were found to recognize diverse antigens, 
peptide and non-peptide, and they play a significant role in anti-infection immunity (27, 28). 
In humans, the first reported γδ T cells response was towards tetanus taxoid (29) but still 
underlying mechanism of recognition remains unclear. Later on, γδ T cells have been found 
to elicit specific response towards soluble bacterial antigens such as toxin listeriolysin and 
staphylococcal enterotoxin and (30-32) In case of the latter, further examination revealed that 
these microbial products acted more like super antigens (33). Other than soluble proteins, γδ 
T cells can recognize non-peptide antigens as well. For example, circulating Vγ9Vδ2 T cells 
recognize phosphoantigens which are low molecular weight prenylated pyrophosphate 
molecules in an MHC independent manner (34, 35). Vδ2+ T cell subset has been shown to 
play role in elimination of microbial pathogens especially intracellular bacteria and has been 
implicated in killing of tumors (36-38). γδ T cells are not yet reported for any MHC-specific 
TCR response but have been recorded for response towards members of CD1 family which 
are structurally MHC- class I like molecule. The group 1 CD1 molecules (CD1a, b, c) 
presents lipid A to Vδ1+ γδ T cells subset and their activation leads to production of IFN- γ 
and granulysin (39, 40). It has been suggested that such activation could provide protection 
against microbial infections prior to development of an antigen specific immune response 
from αβ T cells (40, 41). Additionally, very closely related group 2 CD1d molecule seems to 
present a myelin glycophospholipid called sulfatide to Vδ1 expressing γδ T cells in humans. 
Vδ1+ γδ T cells also respond to stress induced MHC-Class I related molecules MICA/B for 
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which antigen is not required (42). MICA/B molecules are widely expressed by several tumor 
cells which might be recognized by tumor infiltrating Vδ1+ γδ T cells (43).  
 
1.4 Human Vγ9Vδ2 T cells 
Human γδ T cells approximately accounts for 5% of total CD3+ T cell population in 
peripheral blood of a healthy individual (26). Vγ9Vδ2 T cells are major subset of human γδ T 
cells and their T cell receptor (TCR) is formed by pairing of Vγ9-containing γ chain with 
Vδ2-containing-δ chain. Vγ9Vδ2 T cell population ranges from 50% to more than 95% of γδ 
T cells in blood. Interestingly, such dominance was not present at the time of birth but gained 
during childhood and preserved throughout adulthood (26, 44-46) and is finally declining 
with age (47) . Initially, it was identified that broad range of bacteria including 
Mycobacterium tuberculosis could rapidly activate human Vγ9Vδ2 T cells (48). Later it was 
discovered that Vγ9Vδ2 TCRs recognize pyrophosphorylated metabolites of 2-C-methyl-D-
erythritol 4-phosphate (MEP) pathway of isoprenoid synthesis, such as isopentenyl 
pyrophosphate (IPP) and E-4-4hydroxy-3-methyl-byt-2-enyl pyrophosphate (HMBPP) as 
microbial antigens (35, 49). Such pyrophosphate non-peptide metabolites/ligands are 
collectively called as phosphoantigens (PAg). HMBPP is the precursor of IPP in 2-C-methyl-
D-erythritol 4-phosphate pathway (MEP) of isoprenoid synthesis in several eubacteria, plants 
and apicomplexa parasites plants (Fig 3) whereas mevalonate pathway of isoprenoid 
synthesis found in most animals including all vertebrates lacks HMBPP (44, 50). But still, 
human Vγ9Vδ2 T cells recognize endogenous mevalonate pathway intermediates 
accumulated in tumor cells (51) which was later found to be IPP (52). Compared to IPP, 
HMBPP activates Vγ9Vδ2 T cells at least 1000 folds stronger than IPP and is suggested that 
it could be because of its microbial origin (53). Interestingly, accumulation of endogenous 
IPP can be achieved by blocking the consumption of IPP by downstream enzymes such as 
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farnesyl diphosphate synthase (FPPS). Treatment of cells with aminobisphosphonates (such 
as pamidronate or zoledronate) (54), alkylamines (such as sec-butylamine) or even siRNA 
against FPPS has resulted in the accumulation and presentation of IPP, which eventually led 
to the activation of Vγ9Vδ2 T cells (55, 56). Recognition of PAg by Vγ9Vδ2 T cells require 
cell – cell contact or surface receptor mediated presentation of PAg (34, 57). But Vγ9Vδ2 T 
cells recognize antigens in an MHC-independent manner (15) and antigen processing is not 
required (34). Antigen mediated activation of Vγ9Vδ2 TCR, leads to rapid release of 
cytokines such as IFN-γ and TNF-α by these T cells (58, 59). Direct recognition of molecules 
without antigen processing is an advantage of Vγ9Vδ2 T cells over αβ T cells, which makes 
them an attractive tool for anti-tumor therapeutics. In vivo activation of Vγ9Vδ2 T cells has 
been achieved either by direct administration of synthetic phospho-antigens such as 
phosphorylated Bromohydrin (BrHPP) or by administration of aminobisphosphonates (54, 
60). Such a mechanism of activation may enhance their anti-tumor activity and leads to 
eradication of tumor (61).  
Apart from direct activation of Vγ9Vδ2 T cells through PAg, Vγ9Vδ2 T cells can be 
activated or modulated through various molecules such as NK receptors (NKG2D), 
costimulatory and inhibitory molecules expressed by these T cells. NKG2D is a NK cell 
activating receptor which is widely expressed by Vγ9Vδ2 T cells and it is a receptor for 
MHC class 1 related A/B (MICA/B). MICA/B molecules were known as stress induced and 
tumor associated ligands (62). NKG2D mediated activation of Vγ9Vδ2 T cells in a TCR 
independent manner has been reported for the killing of tumor cells by cytotoxic effector 
activity of Vγ9Vδ2 T cells (63). Apart from MICA/B, UL16-binding proteins (ULBP)1-4 
also acts as ligand for NKG2D and several epithelial cancer cells express ULBPs (42). 
Interestingly, association of NKG2D with its ligand (ULBP1) has been reported to promote 
anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria (64). Thus human 
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Vγ9Vδ2 T cells play a significant role in providing first line of defense against infectious 
agents as well as pivotal role in immune and stress surveillance.  
 
Figure 3:  Mevalonate and MEP pathway of isoprenoid synthesis 
a) Mevalonate pathway in vertebrates and 2-C-methyl-D-erythritol 4-phosphate pathway in plants and 
eubacteria are involved in isoprenoid biosynthesis. Isopentenyl pyrophosphate (IPP) is an intermediate found in 
both the pathways. Farnesyl diphosphate synthase (FPPS) is the downstream enzyme which consumes IPP. 
Aminobisphosphonates and alkylamines blocks FPPS which lead to accumulation of IPP.  b) Structure of 
phosphoantigens: HMBPP and IPP adapted from (44). 
 
1.5 Phosphoantigen presentation and Vγ9Vδ2 TCR 
Vγ9Vδ2 T cells are so far identified only in human and primates (60, 65-67) and genes 
homologous to Vγ9 and Vδ2 are absent in mice (4). Unlike conventional αβ T cells, Vγ9Vδ2 
T cells recognize PAg in an MHC independent fashion, but the antigen presenting molecule 
was unknown at the start of this thesis. Most of the human cells of various tissue origins are 
able to elicit PAg mediated activation of human Vγ9Vδ2 T cells but none of the murine cell 
lines can do so. Therefore, it is believed that the antigen presenting molecule is widely 
expressed in human cells but absent in rodents. Several studies have shown that monkey cells 
can present PAg and activate monkey Vγ9Vδ2 T cells (60, 65, 67). Thus, it is widely 
accepted that Vγ9Vδ2 T cell-PAg recognition system is restricted to primates. Ever since the 
discovery of antigen recognized by Vγ9Vδ2 TCRs, identification of the antigen presenting  
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molecule has been a great challenge for the scientific community. In 2012 Harly et al. have 
shown that BTN3A1, a member of butyrophilin family is mandatory for the antigen mediated 
activation of Vγ9Vδ2 T cells (68). BTN3A1 gene is localized at the telomeric region of 
human Chromosome 6 (69) and encodes for a transmembrane protein. It is composed of an 
extracellular domain and an intracellular B30.2 domain. The extracellular domain comprises 
of IgV and IgC domain. BTN3 exists in three isoforms BTN3A1, A2 and A3, and they differ 
largely only with the possession of intracellular B30.2 domain, notably it is absent in 
BTN3A2 (70). In 2013, Vavassori et al. have confirmed that BTN3A1 from Chromosome 6p 
is mandatory for PAg presentation. They also suggested the possibility of BTN3A1 being the 
putative antigen presenting molecule for PAg by demonstrating HMBPP and IPP binding to 
purified BTN3A1, and analysis of co-crystals of BTN3 with these two PAg (71). Recently, 
Wang et al. failed to show binding of HMBPP to the extracellular domain of BTN3A1 and 
suggested, but did not demonstrate, the binding of PAg to the intracellular B30.2 domain of 
BTN3A1. In their study, they also suggested a mechanism for molecular basis of antigen 
presentation, which would involve BTN3A1 and other unidentified molecule(s), for the 
proper loading of PAg and presentation of PAg to Vγ9Vδ2 TCR (Fig 4) (66). So, the 
molecules involved in PAg presentation and the exact mechanism of PAg presentation to 
Vγ9Vδ2 TCR still remain unclear.  
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Figure 4: Model of PAg presentation to Vγ9Vδ2 T cells 
The Vγ9Vδ2 TCRs recognize PAg presented by presenting cell/target cell. The PAg accumulated endogenously 
is presented to Vγ9Vδ2 TCRs in a BTN3A1 dependent manner but exact mechanism is unclear. Different model 
of PAg presentation has been suggested a) BTN3A1 alone independently activate TCR upon intracellular 
binding of PAg. b) BTN3A1 alone independently presenting PAg. c)  Involvement of unknown molecule Mol 
‘X’  in loading presentation of PAg by BTN3A1. d) Endogenously accumulated PAg, bind to intracellular 
domain of BTN3A1 and with/without of involvement of Mol ‘X’, the PAg is loaded and presented by BTN3A1. 
For all the above mode of PAg presentation and activation of TCR other unknown molecules ‘ʮ’ could be 
involved. 
 
1.6 Human/mouse somatic cell hybrids 
Somatic cell hybrids have a long history of being used as a remarkable and an efficient tool 
for the mapping of genes and chromosome as well for the characterization of mechanism that 
regulate gene expression (72). The very first report on somatic hybrids came from Barsky et 
al. who then constructed intra-specific somatic hybrids of mouse origin. Somatic hybrids 
arise as a result of spontaneous cell fusion between cells (73). Three most widely used 
methods to induce fusion of cells were virus induced, chemically mediated or electrical field 
induced fusion (74-76). Human-mouse somatic hybrids were widely used as a tool to 
characterize the phenotype of human chromosomes because of the following reasons; 1) in 
such hybrids the chromosomes from two different parental cells remain segregated. 2) 
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Human/mouse somatic hybrids have the tendency to lose human chromosomes and remain 
stable after retaining 10-20 percent of human chromosome content (77). Thus, such hybrids 
enabled to correlate the functional phenotype of hybrids to human chromosomes, but it was 
necessary to determine the human chromosome being retained by such hybrids. Earlier, 
karyotyping of human chromosome was achieved by staining of chromosomes. The 
technique developed by Caspersson et al. where cells were stained with an alkaline dye, 
quinacrine, which particularly stains chromosomes at specific chromatic regions, and the 
resulting image shows a banding pattern which is called Q-banding (78, 79). This techniques 
paved way to genetic characterization of human chromosome where functional phenotype of 
somatic cell hybrids has been positively correlated to human chromosomes and thereby the 
gene loci for a particular functional phenotype has been assigned (78). In this manner, several 
human genes and their loci on human chromosome have been identified (80-83). But the 
drawback with that technique was difficulty in identification of translocated human 
chromosomes and truncated chromosomes. So, human chromosome specific PCR based 
karyotyping was later developed (84, 85) and has been successfully employed in 
identification of human chromosomes in such somatic hybrids.  
 
1.7 Aims of study 
Vγ9Vδ2 T cells are the major subset of the circulating γδ T cell population and recognize 
PAg. Up to the present moment, Vγ9Vδ2 T cells are identified only in human and higher 
primates. Hence, these cells are believed to be primate specific T cell population and so 
knowledge about Vγ9Vδ2 T cells is limited only to primate models. Identification of other 
species which harbor Vγ9Vδ2 T cells would unravel more on the functional significance and 
antigen recognition properties of these T cells. Hence, we aimed to understand the evolution 
of PAg reactive Vγ9Vδ2 T cells. Therefore, we targeted to investigate the distribution pattern 
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of Vγ9Vδ2 TCR genes and their ligands by performing comprehensive analysis of the 
genomic database for sequences homologous to human Vγ9, Vδ2 and BTN3 genes. If genes 
controlling Vγ9Vδ2 T cell population were to be identified in non-primate species, then those 
were to be further analyzed for the presence of Vγ9Vδ2 T cells and PAg-reactivity. 
Another objective of the thesis is to investigate the molecular basis of PAg presentation 
which could clear up the mystery behind the molecular mechanism of PAg presentation to 
Vγ9Vδ2 T cells. Vγ9Vδ2 TCRs recognize PAg in a BTN3 dependent manner but the exact 
molecular basis of PAg presentation and recognition still remains unclear. To delineate the 
same, we targeted to identify the genes which could be involved in PAg presentation. So the 
primary aim was to identify the chromosome(s) which carry genes necessary for PAg 
presentation. It was proposed that human/rodent somatic hybrids would be used as presenting 
cells to identify the chromosomes involved in PAg presentation. The reason behind the use of 
such hybrids is that they were well known for their ability to lose human chromosomes over a 
period of time. This special feature of these hybrids will enable us to point out the 
chromosomes by loss or gain of function (PAg presentation) of the somatic hybrids. 
Altogether, this thesis aimed to provide valuable data in understanding the evolutionary 
paradigm of Vγ9Vδ2 T cells and to unravel more on the basis of PAg presentation to Vγ9Vδ2 
T cells. 
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2 Material and Methods 
2.1 Materials 
2.1.1 Chemical reagents 
Agar-agar      Roth (Karlsruhe, Germany) 
Ampicilin      Gibco BLR (Eggenstein, Germany) 
Betaine (5M)      Sigma (Germany) 
Β-mercaptoethanol     Gibco BLR (Eggenstein, Germany) 
Calcium Chloride (CaCl2)    Roth (Karlsruhe, Germany) 
DMSO (Dimethyle sulfoxide)   Sigma (Taufkirchen, Germany) 
dNTP       NEB (Frankfurt, Germany) 
Boric acid      Roth (Karlsruhe, Germany) 
EDTA       AppliChem GmbH (Darmstadt, 
Germany) 
Ethanol      AppliChem GmbH (Darmstadt, 
Germany) 
Ficoll paque (LSM1077)    PAA laboratories GmbH (Austria) 
Formaldehyde      Roth (Karlsruhe, Germany) 
Glycerol      Sigma (Schnelldorf, Germany) 
Hypozanthine-Aminopterin-    Sigma (Steinheim, Germany) 
Thymidine (HAT) 
 
Hypozanthine-Thymidine (HT)   Sigma (Steinheim, Germany) 
HMBPP      Dr. Sabine Amslinger, University of    
       Regensburg 
 
Hygromycin      Sigma 
IPP       Sigma (Diesenhofen, Germany) 
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Isopropanol      AppliChem GmbH (Darmstadt, 
Germany) 
LB (Broth Base medium)    Gibco BLR (Eggenstein, Germany) 
Methanol      AppliChem GmbH (Darmstadt, 
Germany) 
Polyethyleneglycol (PEG)    Boehringer Mannheim (Germany) 
Penicillin      Gibco BLR (Eggenstein, Germany) 
Polybrene      Sigma (Diesenhofen, Germany) 
Recombinant human IL-2 (rhuIL-2)   Miltenyi Biotec (Germany) 
Sodium Butyrate (Na-Butyrate)   Sigma (Diesenhofen, Germany) 
Sodium Azide (NaN3)     Merck (Darmstadt, Germany) 
Sodium Chloride      Roth (Karlsruhe, Germany) 
Tris (hybroxymethyl)-aminomethan (Tris)  AppliChem GmbH (Darmstadt, 
Germany) 
Trypan blue      Sigma (Diesenhofen, Germany) 
Tween20      Sigma (Diesenhofen, Germany) 
Zeocine      Cayla (Toulouse Cedex, France) 
Zoledronate      Novortis (Basel, Switzerland) 
8-Azaguanine      Sigma (Steinheim, Germany) 
 
2.1.2 Media, solutions and buffers 
Media used were supplied by Gibco-BRL (Eggenstein, Germany) 
Dulbeccos’s Modified Eagles’s Medium (DMEM)  
- With pyruvate, without HEPES 
- Without pyruvate, with HEPES 
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RPMI     RPMI 1640 + L-Glutamine 
Supplement complete  500 ml heat deactivated FCS  
(SC; 50ml/500 ml Medium) 100 ml Na pyruvates 100mM 
    100 ml non-essential amino acids 
    5 ml β-mecrcaptoethanol 50 mM 
    100 ml Penicllin – Streptomycin (1000U/ml) 
    58.4 ml L-Glutamine Solution 5% 
ATV    0.05% Trypsin, 0.02% EDTA in PBS 
2 x HBS (pH 7.05) 50 mM HEPES pH 7.05, 10 mM KCL, 12 mM Glucose,            
280 mM NaCl, 1.5 mM NaHPO4 
LB medium 20 g LB in 1000 ml dH2O, autoclaved and stored at 4 
o 
C 
Phosphate buffered saline (PBS)  4 mM KH2PO4, 16 mM Na2HPO4, 115 mM NaCl, pH 
7.3 
PBS/BSA/Azide 0.2% BSA, 0.02 % Na-Azide in PBS 
10x TBE 890 mM Tris pH 8.0, 890 mM Boric acid, 20 mM EDTA 
FACS buffer  0.1% BSA, 0.05% NaN3 in PBS 
Cell freezing solution 50% FCS, 40% RPMI, 10% DMSO 
 
Buffers for ELISA 
Coating Buffer (100ml)  0.84 g NaHCO3, 0.356 g Na2CO3 ddH2O pH 9.5 
Assay Dilute    PBS with 10% FCS, pH 7.0 
Wash Buffer    PBS with 0.05% Tween20 
Stop Solution    2M H2SO4 
 
 
Materials and Methods 
16 
 
2.1.3 Cell lines 
RAJI  Human Burkitt lymphoma cell line (ATCC CCl-86) 
Jurkat  Human T cell leukemia cell line (ATCC TIB-153) 
293T  Human embryonic kidney cell line (ATCC CRL-1573) 
A20  Mouse B lymphoma cell line (ATCC TIB-208) 
BW5417 Mouse thymoma cell line (negative for expression of αβ TCR) 
BW58  Mouse hybridomas derived AKR/J mouse αβ TCR-negative cell lymphoma 
(86) 
BW58r/mCD28 BW58 cells transduced with r/m CD28 (87) 
L929  Mouse fibroblast cells line (ATCC CCL-1) 
COS  Fibroblast cell line derived from monkey kidney tissue (ATCC CRL-1651) 
 
2.1.4 Vectors 
pVSV-g  pCZVSV-g containing env form Vesicular Stomatitis Virus (88) 
pHIT-60 CMV-MCC-gag-pol-SV40ori; vector carries human cytomegalovirus (CMV) 
promoter under which gag and pol genes from Moloney Murine Leukemia 
Virus (MoMLV) were controlled (89) 
pczCG5IEGZ Retroviral vector for the MuLV driven constitutive expression of gene of 
interest and IRES mediated expression of EGFP – zeocine resistant fusion 
protein  
pIH Retroviral vector for the MuLV driven constitute expression of gene of 
interest with hygromycin resistant gene expression 
pIZ Retroviral vector for the MuLV driven constitute expression of gene of 
interest with zeocine resistant gene expression 
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2.1.5 Antibodies 
Antigen Clone Conjugated Isotype Manufacturer 
mCD3ε 145-2C11 Bio Hamster IgG1,κ BD Pharmingen 
hCD71 M-A712 FITC mIgG2a, κ BD Pharmingen 
HLA-ABC G46-2.6 FITC mIgG1, κ BD Pharmingen 
rCD80 3H5 Purified mIgG1, κ BD Pharmingen 
huVδ2 chain B6 PE mIgG1, κ BD Pharmingen 
 
Secondary antibodies commonly used for the staining were against mouse IgG (H+L). 
Antibody used was donkey (Fab’) 2 fragments with minimal cross reactivity towards rat and 
other serum proteins. Antibody was either conjugated with FITC/PE and was supplied by 
Jackson Immunoresearch Laboratories. 
 
2.1.6 Cloning reagents 
Taq DNA polymerase 2x PCR mix  Fermentas (St.Leon-Rot, Germany) 
One Taq Hot start DNA polymerase  NEB (Frankfurt, Germany) 
One Taq 2x master mix   NEB (Frankfurt, Germany) 
Pfu-DNA polymerase    Finnzymes (Espoo, Finnland) 
Restrictions enzymes     Fermentas (St.Leon-Rot, Germany) 
(EcoRI, BamHI, BglII, XhoI, Xba1)  
 
2.1.7 Kits 
Mini Elute Gel Extraction Kit  Qiagen (Hilden, Germany) 
Big Dye 3.1      AB applied biosystems (California, USA) 
GeneJET Plasmind Minipret Kit  Fermentas (St.Leon-Rot, Germany) 
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JET quick DNA clean Up Spin Kit  Genomed (Löhne, Germany) 
Midi JETSTAR Kits    Genomed (Löhne, Germany) 
QIAamp DNA mini Kit   Qiagen (Hilden, Germany) 
RNAeasy Mini Kit    Qiagen (Hilden, Germany) 
QIAshredder     Qiagen (Hilden, Germany) 
OPTEIA mouse IL-2 Set   BD (Heidelberg, Germany) 
GeneRacer® Kit with AMV RT and   Life technologies (Germany) 
TOPO TA Cloning® Kit for Sequencing 
 
 
2.1.8 Consumables 
6 well flat bottom culture plates   Greiner Bio-One (Germany) 
12 well flat bottom culture plates   Greiner Bio-One (Germany) 
24 well flat bottom culture plates   Greiner Bio-One (Germany) 
48 well flat bottom culture plates   Greiner Bio-One (Germany) 
96 well U bottom culture plates   Greiner Bio-One (Germany) 
6 cm tissue culture dish    Greiner Bio-One (Germany) 
50 ml cell culture flask    Greiner Bio-One (Germany) 
5, 15 and 25 ml single use pipettes   Greiner Bio-One (Germany) 
1.5 ml Eppendorf centrifuge tube   Eppendorf (Eppendorf, Germany) 
15 ml centrifuge tube 50 ml centrifuge tube Greiner Bio-One (Germany) 
Cuvette      Bio-Rad (Munich, Germany) 
10 μl tips      Molecular Bioproducts (USA) 
200 μl yellow tips     Roth (Karlsruhe, Germany) 
1000 μl blue tips     Roth (Karlsruhe, Germany) 
5ml single-use syringe    BD Biosciences Pharmingen (San Diego, USA) 
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2.1.9 Software 
Cell Quest and FlowJo: For the analysis of flow cytometry data 
MEGA: For the construction of Phylogenetic tree to understand the phylogenetic relationship 
between different sequences and species 
Endnote: Tool for the management of bibliographies 
 
2.1.10 Primers used for PCR and RACE  
Horse Vδ2 Rev  GAAGGAAGAACGATGGAACATTTATTGAC 
Horse Vγ9 Rev GAGCGGATGTGCTAACAGTGGTGAGGAC 
Horse Vδ2 Fwd GCAAACGCCCTCTTGGGGAACAAAACAGCAG 
Horse Vδ2 Rev GCAGAAGAGTGACCGAGGCTGAAGGAAAGG 
Alpaca Vγ9 Fwd GTGCAGGTCATCTAGAGCAACCGC 
Alpaca Vγ9C Rev TCCATTGACTTTTCAGGCACGGTCA 
Alpaca Vδ2 Fwd GTCAGCAGATGTGTTGGTGCCTCA 
Alpaca Vδ2 C Rev CCAGCACCGAGAGGGACATCATGT 
Alpaca JC Fwd CGGCTCATTATTACAGACAGAAAGCTTGATG 
3’RACEQt CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCTTTTTTTTTTTTT
TTTTVN 
3’RACEQo Rev CCAGTGAGCAGAGTGACGAGGAC 
3’RACEQi Rev TGACGAGGACTCGAGCTCAAGC 
Alpaca Vγ9 5’UTREcoRI TTCCGAATTCGCCGCCACCACAGTGCGGTCCATCCAGACATG 
Alpaca Cγ9 3’UTR ATCCGGATCCGAGAAGTTCAGAGCAACAGACGAT 
Alpaca Vδ2Ldr ATGCAGAGGGTCTGCTCCCTCATCC 
Alpaca Vδ2 Ldr EcoRI CAGTGAATTCGCCGCCACCATGCAGAGGGTCTGCTCCCTCATCC 
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Alpaca Cδ2 3’UTR TCACGGATCCCCTCACCATTCCTAAATTCCTTT 
AGMγ9EcoRIKozakFwd CTACGAATTCGCCGCCACCATGCTGTCACTGCTGCTCCACGC 
AGMγ9BglIIRev CCACAGATCTTTACGGTCTCTCTCCATTGCAGC 
AGMδ2EcoRIKozakFwd CTACGAATTCGCCGCCACCATGATCTCCTCCCTCATCCATCT 
AGMδ2BglIIRev CCACAGATCTTTACAAGAAAAATAACTTGGCAG 
Generacer5’fwd CGACTGGAGCACGAGGACACTGA 
AlpacaBTN3stopRev3 CTAGGCAGGGACAAGCAAGGATG 
VpBTN3RaceQoRev1 CTGTCTTCTACTTCCTTCCCACCTGCGT 
CowVγ9Fp1 GCTTGTAAGTTGTTCTTTTCCCCCAATTTC 
CowVγ9Rp1 GTGGTAACTGTGGTTTCCTAACTCACGATA 
CowVδ2Fp1 GGACCAGGCAAGAACGAGTCAGGAGGCAGAGC 
CowVδ2Rp1 AGGGATTGCCTATCTGAGCACCACGGGAG 
 
2.1.11 Accession number of genomic sequences 
VGamma9: 
ABRR01244317.1 -  Alpaca ( Vicugna pacos), AAGV03121505.1 – Armadillo (Dasypus 
novemcinctus), AGTM011099715.1 – Aye-aye(Daubentonia madagascariensis), 
AGVR01031390.1 – Wild bactrian camel (Camelus bactrianus), gb|GADY01006660.1 -
Dromedary (Camelus dromedarius), AGCE01067087.1 – Black capped squirrel monkey 
(Saimiri boliviensis), AJFE01038666.1 – Bonobo (Pan paniscus), ABRN02028896.1 – Bottle 
nose dolphin ( Tursiops truncates), AACZ03050974.1 -  Chimpanzee (Pan troglodytes), 
ACFV01091880.1 – Common marmoset (Callithrix jacchus), DAAA02011292.1 – Cow (Bos 
Taurus), ABRP01014493.1 – Flying fox (Pteropus vampyrus), ADFV01046571.1 – Gibbon 
(Nomascus leucogenys),CABD02337330.1 – Gorilla (Gorilla gorilla gorilla), 
ABDC01371517.1 – Grey mouse lemur (Microcebus murinus ), AAWR02031701.1 – Horse 
(Equus caballus), AEHL01292420.1 – Japanese Macaque (Macaca fascicularis), 
ANOL02003608.1 – Killer whales (Orcinus orca), AAQR03057839.1-  Northern greater 
Galago (Otolemur garnettii), ABGA01290208.1 – Oranguttan (Pongo abelii), 
ABRT010177380.1 – Philippine tarsier (Tarsius syrichta), AANU01218521.1 -  Rhesus 
monkey (Macaca mulatta), AMGL01088491.1 -  Sheep (Ovis aries), ABVD01168789.1 – 
Sloth (Choloepus hoffmanni), AGTP01012576.1 -  Thirteen lined ground squirrel (Ictidomys 
tridecemlineatus), AGTT01041789.1 – Tibetan antelope (Pantholops hodgsonii), 
AKZM01048251.1 – White rhinoceros (Ceratotherium simum simum), AOCR01006132.1 – 
Wild boar (Sus scrofa), AJPT01047514.1 -  Yunnan black goat (Capra hircus) 
Alpaca (Vicugna pacos) Genomic JP segment - gb|ABRR02020993.1 
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VDelta2: 
AAGU03084666.1 – African elephant (Loxodonta Africana), ABRR01280573.1-  Alpaca ( 
Vicugna pacos), AAGV03208792.1– Armadillo (Dasypus novemcinctus), 
AGTM011787934.1– Aye-aye(Daubentonia madagascariensis), AHZZ01035404.1 – Baboon 
(Papio anubis), AGCE01026517.1 – Black capped squirrel monkey (Saimiri boliviensis), 
ALWS01051822.1 - Black Flying Fox (Pteropus alecto), ALEH01136097.1 - Big Brown Bat 
(Eptesicus fuscus), AJFE01024273.1– Bonobo (Pan paniscus), ABRN02535067.1– Bottle 
nose dolphin ( Tursiops truncates),  AMDV01053035.1 - Cape golden mole (Chrysochloris 
asiatica), ACBE01202348.1 - Cat (Felis catus), AACZ03095321.1-  Chimpanzee (Pan 
troglodytes), ACFV01031202.1– Common marmoset (Callithrix jacchus), 
DAAA02028054.1– Cow (Bos Taurus),  ALWT01226188.1 -David’s Mouse eared bat 
(Myotis davidii), AAPE02039938.1 - Fruit bat (Myotis lucifugus), ABRP01238689.1– Flying 
fox (Pteropus vampyrus), ACTA01003783.1 - Giant Panda (Ailuropoda melanoleuca, 
ADFV01192055.1– Gibbon (Nomascus leucogenys), CABD02105635.1– Gorilla (Gorilla 
gorilla gorilla), ABDC01133592.1– Grey mouse lemur (Microcebus murinus ), 
AAWR02001688.1– Horse (Equus caballus), AEHL01378925.1– Japanese Macaque 
(Macaca fascicularis), ANOL02066598.1– Killer whales (Orcinus orca), AHIN01142883.1 – 
Manatee (Trichechus manatus latirostris), AAQR03175671.1 -  Northern greater Galago 
(Otolemur garnettii), AAPY01347909.1 – Norther Treeshrew (Tupaia belangeri), 
AEHK01331688.1-  Rhesus monkey (Macaca mulatta), AMGL01102217.1-  Sheep (Ovis 
aries), ABVD01106723.1– Sloth (Choloepus hoffmanni), AJFV01075663.1 - Star nosed 
mole (Condylura cristata), , AGTT01175372.1– Tibetan antelope (Pantholops hodgsonii), 
AKZM01006933.1– White rhinoceros (Ceratotherium simum simum), gb|AJKK01135927.1– 
Wild boar (Sus scrofa), AJPT01105872.1-  Yunnan black goat (Capra hircus) 
 
BTN3-ED: 
 NM_001145008.1 - Human (Homo sapiens); gb|ABRR02153549.1 – Alpaca (Vicugna 
pacos); tpg|DAAA02055496.1 – Cow (Bos taurus); gb|ABVD01029026.1, 
gb|ABVD01842615.1 – sloth (Choloepus hoffmanni); gb|ABDC01331604.1- Grey mouse 
lemur(Microcebus murinus), gb|AGTM011755245.1 - Aye-aye (Daubentonia 
madagascariensis); gb|AAWR02009770.1, gb|AAWR02009775.1 – Horse (Equus Cabalus), 
gb|AAGV03145787.1, gb|AAGV03240342.1 - Nine Banded Armadillo (Dasypus 
novemcinctus); gb|ABRN02268951.1, gb|ABRN02485746.1- Bottlenose Dolphin (Tursiops 
truncates); gb|ANOL02034815.1Killerwhales (Orcinus Ocra); gb|AGTP01091243.1, 
gb|AGTP01091244.1 - Thirteen lined squirrel (Ictidomys tridecemlineatus); 
gb|ABRT010776711.1, gb|ABRT010215784.1 - Philippine tarsier (Tarsius syrichta);  
gb|AJPT01202731.1 - Yunnan black goat (Capra hircus);  gb|GAES01012686.1, 
gb|GAEX01008159.1 – Wild bactrian camel (Camelus ferus); gb|ACIV011865666.1 – 
Sheep(Ovis aries), gb|AGTT01201962.1 - Tibetan antelope (Pantholops hodgsonii); 
gb|AAPE02057860.1 - Fruit bat (Myotis lucifugus); gb|AKZM01051838.1 - White 
Rhinoceros (Ceratotherium simum simum); gb|ALWT01109578.1 -David’s Mouse eared bat 
(Myotis davidii); gb|ALEH01160890.1 - Big Brown Bat (Eptesicus fuscus). 
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2.2 Methods 
2.2.1 Routine cell culture methods 
The mammalian cells were cultured in a CO2 cell incubator in which 37
0
C with 5% CO2 and 
H2O saturated atmosphere was maintained. Almost all suspension cells were cultured with 
RPMI medium (10% SC) whereas adherent cells were maintained with DMEM medium 
(10% FCS, 1 ml Penicillin – Streptomycin (100mg/ml) per 500ml DMEM). For routine 
maintenance, suspension cells were cultured in 24/12 well plates and adherent cells were 
maintained always in 10cm tissue culture dishes. Frozen stocks of cells were always 
maintained at -80
0
 C or -140
0
C. 1*10
6
 - 4*10
6
 cells were re-suspended in 1ml of freezing 
medium (50%FCS, 40% RPMI and 10% DMSO) and stored in a pre-chilled 2ml cryo tubes. 
Whenever required the stocks were defrost and cells were cultured. Prior to every 
experiment, cells used for the experiment were counted. Percentage of viable cells was 
determined by diluting cells with Tryphan-blue solution and counted with Neubauer chamber 
under the microscope. Those cells remaining unstained are considered as live ones and are 
counted.  
 
2.2.2 Isolation of peripheral blood mononuclear cells (PBMC) 
PBMC were isolated from the fresh blood obtained from healthy donors under informed 
consent or from blood of alpaca provided by Prof. Thomas Göbel, Institute for animal 
physiology, Ludwig-Maximilians-University, Munich Separation of PBMC was performed 
using Ficoll Paque (lymphocyte separation medium (LSM-1077)) supplied by PAA as per 
manufacturer’s protocol. In a 50 ml conical tube, 20 ml of whole blood was transferred and 
equal volume of PBS was added to it. 10 ml of Ficoll was released at the bottom of the tube 
gently to avoid the mixing of blood and fecal. Finally, blood will be layer on the Ficoll and 
the tube was centrifuged at 400x g for 30 min at 20
0
C min with brakes applied. After 
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centrifugation, PBMC concentrated as an interphase layer between plasma and the separation 
solution was aspirated with a pipette and transferred to a new 15 ml tube and washed twice 
with 3 volumes of PBS at 400x g for 10 min. Finally, PBMC were resuspend in 1 ml of 
RPMI (10% SC).  
 
2.2.3 Construction of human/mouse hybridoma 
a) Prior to beginning of the fusion, 100ml of RPMI 1640 medium and 50 ml of RPMI 1640 
medium with 10% serum complement was warmed up.  
b) 5x10*6 cells of Jurkat cells and BW5417 cells were taken for fusion in 1:1 ratio as human 
and mouse cells, were chosen for fusion.  
c) Both cell types were mixed and make up to 50ml with RPMI 1640 medium in a 50ml 
tube..  
d) The cell suspension was centrifuged at 461 x g per minute for 5 minutes. 
e) After centrifugation, the supernatant was removed and the cell pellet was generally 
tapped to break the pellet. Meanwhile, water-bath was warmed to 37
0
C for the following 
steps. 
f) The tube was placed in the water-bath with continuous gentle shaking of the tube and 5 
ml of RPMI 1640 medium was added slowly drop by drop along the wall for 5 minutes.  
g) 10ml of RPMI 1640 medium was added in a similar fashion for 5 minutes. 
h) Then 30ml of RPMI 1640 (10% SC) was added slowly and incubated the tube in 370C in 
water-bath for 30 minutes. 
i) After incubation, the cell suspension was centrifuged for 461 x g for 5 minutes. 
j) After centrifugation, the supernatant was discarded and the cell pellet was resuspended 
slowly in 25 ml of RPMI 1640 (10% SC). Further cells were diluted to 1 cell/100μl 
concentration and cells were seeded in 96 well plate with single cell per well dilution. 
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After 24 hours, 100μl of 2xHAT and antibiotics (Hygromycin - 500μg/mL and Zeocine - 
500μg/mL) were added to each well and clones were selected for two weeks. 
k) In a similar manner human PBLs (1x107 cells) and BW 5147 (5x106) cells were fused to 
construct hybridomas. 
 
2.2.4 Gene cloning and transfer 
2.2.4.1 Genomic DNA isolation from hybridomas 
The clones screened for their antigen presentation ability were subjected to PCR 
Karyotyping. The genomic DNA was isolated from 200,000 cells of each clone by treating 
them with 200 μl lysis buffer (10mM Tris, 50mM KCl, 2mM MgCl2, 0.1% TritonX100, 0.5% 
Tween20) containing 10μg/mL proteinase K by incubating at 370C for an hour and incubated 
at 96
0
C for 30 minutes to completely lyse the cells. The lysate was used a template for PCR 
Karyotyping.  
 
2.2.4.2 Genomic DNA isolation and Total RNA extraction from PBMC 
Genomic DNA was prepared using the Qiagen genomic DNA isolation kit. RNA was 
prepared using the Qiagen RNeasy kit. The concentration of eluted DNA and RNA was 
estimated by with absorbance at 260nm by using Nanodrop.  
 
2.2.4.3 cDNA synthesis 
cDNA was prepared from RNA by following the manufacturer’s protocol. Fermantas First 
strand cDNA synthesis kit and oligo dT primers provided with the kit was used for cDNA 
synthesis. 
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2.2.4.4 PCR amplification 
Different polymerases were used for different purposes. Taq DNA polymerase (2xPCR 
Master Mix, Thermo Scientific) was used for the PCR karyotyping and screening of genes. 
Phusion high-fidelity DNA polymerase (Thermo Scientific) was used for PCR reactions to 
amplify the genes for cloning and sequencing. One Taq Hot Start DNA polymerases were 
used for 3’ and 5’ RACE PCR conditions to amplify the unknown cDNA ends. For all 
polymerases reaction mix was prepared as per manufacturer’s protocol. Below mentioned 
were the conditions followed for different polymerases. 
PCR Conditions 
Taq DNA 
polymerase 
Phusion high-
fidelity DNA 
polymerase 
One Taq Hot Start 
DNA polymerase 
Initial denaturation 94
0
C, 5 mins 98
0
C, 30 sec 94
0
C, 30 sec 
Denaturation 94
0
C, 15 –  30 sec 980C, 10 sec 940C, 15 –  30 sec 
Annealing Variable, 15-60 sec Variable, 20 sec Variable, 15-60 sec 
Extension 72
0
C, 1 min/Kb 72
0
C, 30 sec/Kb 68
0
C, 1 min/Kb 
Final extension 72
0
C, 10 mins 72
0
C, 10 mins 68
0
C, 10 mins 
 
2.2.4.5 5’ and 3’RACE PCR 
5’RACE PCR was performed to amplify the unknown 5’ end of gene sequence by using 
GeneRacer kit supplied by Life technologies. Similarly 3’ RACE PCR was performed using 
One Taq Hot Start polymerase supplied by NEB following the published protocol (90).   
 
2.2.4.6 Gel electrophoresis  
5 μl of PCR product will be mixed with 1 μl of 6x loading dye and loaded on 1% or 2% 
agarose gel with an appropriate DNA ladder (100bp/1Kb ladder). Agarose gels were made 
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with GelRed nucleic acid gel stain. After electrophoresis, gels were visualized under UV 
illuminator.  
 
2.2.4.7 Digestion and ligation of PCR products and plasmid 
PCR products were either purified by QIAquick PCR purification kit or after gel 
electrophoresis; the appropriate gel was excised and purified by Qiagen gel extraction kit. 
The PCR product and vector was digested with suitable restriction enzymes under 
recommended conditions as per manufacturer’s protocol. The digested products were 
separated by gel electrophoresis and the right size bands were excised and DNA was 
extracted from gels by Qiagen gel extraction kit. 5 μl of digested PCR product/gene and 1 μl 
digested vector was added to a mixture containing 1μl of T4 DNA ligase, 1μl of 10X ligation 
buffer and 2μl of water. Ligation reaction was set at 40C overnight. 
 
2.2.4.8 Transformation 
1.5ml eppendorf vial containing 50 μl of frozen competent cells was placed on ice for several 
minutes. Once the competent cells have been thawed, 3 μl of ligation mix was mixed to 50 μl 
of competent cells and placed on ice for 10 min. After 10 min, competent cells were given a 
heat shock treatment of 42
0
C for 30 sec. Immediately it was placed on ice for 2 min and 250 
μl of LB/SOC medium was supplemented to the competent cells and incubated in a shaker 
incubator for 45 min at 37
0
C with 180rpm. Soon after the incubation period, the transformed 
cells were spread on two LB-Agar plates with appropriate antibiotics and incubated overnight 
at 37
0
C. Resultant colonies were picked and inoculated in 5ml of LB-broth for plasmid mini-
prep to characterize the plasmid.  
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2.2.4.9 Miniprep and identification of positive clones 
Several tubes containing 5ml of LB-broth and appropriate antibiotic for selection were 
inoculated with single colonies and were incubated overnight at 37
0
C in a shaker incubator at 
180 rpm. After incubation, 2 ml of bacterial culture was used to prepare plasmid DNAs with 
the Miniprep kit supplied by Genomed. 2 μl of plasmid DNA was digested with appropriate 
restriction enzymes for an hour and they were tested on the gel by electrophoresis. The 
positive clones were further purified by plasmid clean up kit supplied by Genomed. 
 
2.2.4.10 Sequencing 
The plasmid and PCR products were analyzed by sequencing. The samples to be sequenced 
were PCR amplified using BigDye® Terminator v3.1 Cycle Sequencing Kit supplied by Life 
technologies. The amplified PCR sample was in-house sequenced by the Sanger sequencing 
method using ABI PRISM 310 Genetic Analyzer. 
 
2.2.4.11 Retroviral transduction 
To express our gene of interest in mammalian cells, viral particle mediated transduction of 
the gene was employed. Three-plasmid expression system (retro virus) is used, where 293T 
cells were transfected with three plasmids by calcium chloride. As a result virus particles 
were generated by 293T293T cells and released in the supernatant. Which was later, used to 
infect target cells. The procedure is detailed as below and is adapted from (89), 
Day1:  1.5*10
6
 293T cells were seeded on 6 cm tissue culture dish with 5ml of DMEM. 
Three vectors (Recombinant vector, pHIT60, pVSV-G), each of 5 μg was mixed and 
precipitated with 500 μl isopropanol and washed with 500 μl of 70% ethanol. Later air dried 
in a sterile environment and resuspend in 100 μl of sterile water.  
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Day 2: Culture medium of 293T cells was replaced with warm, fresh DMEM medium 
without HEPES and incubated for an hour in incubator to allow the pH to reach equilibrium. 
Later, 338 μl of water and 62 μl of 2M CaCl2 were added to 100 μl of plasmid DNA. The 
above mixture of DNA was transferred to 500 μl of 2X HBS solution in a drop by drop 
manner and mixed simultaneously by bubbling. Immediately, DNA mixture was poured all 
over the 293T culture dish in a drop by drop manner and mixed gently. The culture dish was 
incubated for 6-8 hours at 37
0
C and the medium was replaced with a fresh warm medium 
with HEPES. Cells were incubated overnight in same condition. 
Day 3: The culture medium was replaced with fresh and warm DMEM medium containing 
10mM sodium butyrate. Sodium butyrate activates the CMV promoter, which in turn induces 
the expression of genes of interest as well as genes necessary for the formation of viral 
particles. 6-8 hours later, the sodium butyrate medium was replaced with fresh warm medium 
without sodium butyrate and cells were incubated overnight. 
Day 4: Final day of infection, where the supernatant from 293T cell culture dish will be 
filtered by 0.45μM filter, ensure the filtering of cells but not viral particles. The target cells of 
1*10
5
 cells taken in a 15 ml tube will be supplemented with 3ml of viral supernatant and 
Polybrene (final concentration; 4 μg/ml). The tubes were centrifuged at 871 x g for 150 min 
at 32
0
C. Soon after centrifugation, the supernatant was aspirated and the cell pellet was 
resuspend in 3ml of fresh medium and cultured in a 12 well plate.   
 
2.2.4.12 Identification and selection of transduced cells 
Once the cells were transduced with gene of interest, cells will be cultured with medium 
supplemented with appropriate antibiotics (puromycin, neomycin or zeocin) for 2-3 days. 
Later, cells were analyzed by FACS for the expression of fluorescent proteins like GFP, YFP 
and AsRed or stained with antibodies against the protein of interest. Once the cells were 
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found to be positive for gene of interest, after a week or two of selection duration, cells will 
be cultured without antibiotics. If the positive cell population is too less, then positive cells 
were sorted by a FACS Aria III machine and cultured with selection medium. 
 
2.2.5 Mouse IL-2 assays 
Stimulation of TCR transductants mouse cells by antigen presenting cells in presence of 
antigen is the method to analyze the ability of cells to present antigen and capability of TCR 
transductants to recognize antigens. For stimulation, TCR transductants were co-cultured 
with APCs in presence and absence of antigen for overnight at 37
0
C. The supernatant of 
stimulation samples were analyzed for the production of mouse IL-2. Measuring of IL-2 was 
performed by using mouse IL-2 ELISA kit supplied BD biosciences as per manufacturer’s 
protocol.  
 
2.2.6 PCR Karyotyping 
Hybridomas were analyzed for genomic content by PCR; the primers used for the screening 
were previously reported as human genome specific ones and were used for screening such 
human/mouse and human/hamster hybrids (84, 85). The PCR conditions to amplify 
chromosome specific product was below mentioned in the table and were reported previously 
(84, 85).  
 
Temperature ProgramA C D E 
90
o 
C 10 sec 10 sec 10 sec 1 min (94
o 
C) 
Annealing Tm 55
o 
C  
30 sec 
50
o 
C 
30 sec 
48
o 
C 
30 sec 
65
o 
C 
2 min 
72
o 
C 30 sec 30 sec 30 sec 3 mins 
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List of Chromosomes amplified with each PCR condition: 
Prog A: 1, 2, 7p, 10p, 12, 13, 17p, 20, X 
Prog C: 3, 5, 8, 9p, 11 
Prog D: 4, 6, 18 
Prog E: 14, 15, 16, 19, 21, 22 
 
2.2.7 Phylogenetic analysis 
Human Vγ9, Vδ2 and BTN3-ED gene sequences were taken as a query in search of Vγ9, Vδ2 
and BTN3-ED like genes in other mammalian species. The query sequence was blasted 
against mammal whole-genome shotgun database using the discontinuous megablast 
algorithm at NCBI BLAST. Hits which covered at least 90% of V genes in length and with at 
least 60% sequence identity to the query sequence were chosen for analysis. Other than NCBI 
BLAST, genomic sequence assembly released by the Broad institute 
(http://www.broadinstitute.org/science/projects/mammals-models/data-release-mammalian-
genome-project, which is now available at the NCBI database) was also used to perform the 
search for human Vγ9, Vδ2 and BTN3-ED like nucleotide sequences. All the sequences 
obtained from databases were translated in silico using Expasy Translate 
(http://web.expasy.org/translate/) to identify the presence of open reading frames. The amino 
acid sequences were aligned using the ClustalW2 tool 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Phylogenetic analyses were performed using 
MEGA software - version 5.2. The nucleotide sequences of human Vγ9, Vδ2 and BTN3-ED 
and their respective homologous sequences identified in several species were analyzed for 
phylogenetic studies. The phylogenetic trees were constructed by the several methods with 
bootstrap test and interior branch-test of 10000 replications. Such phylogenetic methods 
include; maximum parsimony method, maximum likelihood method, neighbor joining 
method and minimum evolution method. For every method, trees were constructed with 
bootstrap frequency and branch length as determinants of confidence of each node in a tree. 
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Each node represents each species branching out from the backbone of the tree. Higher the 
bootstrap frequency, greater the confidence of node whereas in case of branch length, lower 
the value higher the strength of node. The values indicate the probability for phylogenetic 
relationship between species at every node. Since, all three methods yielded similar trees with 
similar bootstrap confidence for each node in a tree, the phylogenetic trees obtained on 
maximum likelihood method was finally presented since it is widely accepted for the analysis 
of phylogenetic relationship between distinct species. 
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3. Results 
3.1 Evolution of Vγ9 and Vδ2 TCR genes and BTN3 gene 
3.1.1 Vγ9 and Vδ2 genes emerged with and are scattered across placental mammal 
Vγ9Vδ2 T cells have been found only in higher primates and not been described in rodents. 
To learn whether such cells may occur in other species than higher primates a database search 
for genes constitutive for functional Vγ9Vδ2 T cells was performed. A search for Vγ9, Vδ2 
and BTN3 genes (putative antigen presenting molecule) was done across mammalian whole 
genomic databases (whole-genome shotgun contigs and 29 mammals project on Broad 
Institute database) by the criteria of more than 60% nucleotide identity and 90% coverage of 
the query (human) sequences. As a result, we found that Vγ9, Vδ2 and BTN3 homologous 
sequences are distributed among species belonging to either of the eutherian magnorders (Fig 
5, Table 1). Furthermore, these genes are completely absent in non-eutherian species (data 
not shown). This is a clear indication that these genes emerged and evolved along with the 
emergence or placental mammals and that they are not restricted to primates. The gene 
sequences identified from different species were reverse blasted against human genome and 
transcript database and human Vγ9, Vδ2 and BTN3-ED appeared as the first hit for respective 
query sequence. Hence the gene sequences which have been identified in the different species 
were claimed as being homologous to human genes. The interesting revelation from the 
search is that the three genes are not universally preserved among mammals and exhibit a 
heterogeneous pattern of distribution. For instance, Vγ9, Vδ2 and BTN3 like genes are 
preserved by most of the species of the order Primata and to the contrary, these genes are 
completely absent in all species belong to the orders like Lagomorpha (Fig 5, Table I). 
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Figure 5: Distribution of Vγ9 and Vδ2 genes among mammals 
The figure represents the distribution of Vγ9/Vδ2 and BTN3 among the different orders belonging to Placentalia. 
Human Vγ9/Vδ2 and BTN3 IgV-IgC nucleotide sequences were taken as query and blasted against whole-
genome shotgun contigs (NCBI) to search for homologous sequences across all organisms available in the NCBI 
database. The search was performed using the megablast algorithm to obtain even the distinct sequences that are 
<60% identical to the query sequence. Plus – indicates Collective representation of the presence of genes in all 
the species belonging to an order. Minus – Indicates the complete absence of genes in the order. Plus/minus- 
indicates the heterogeneous distribution of genes across the species belonging to the order. Mya – Million years 
ago represent the period of origin of superorders (91).  
 
The Crown Placentalia splits into the two Magnorders; Atlantogenata and Boreoeutheria. 
These split into the superorders Afrotheria and Xenarthra belonging to the Atlantogenata and 
Euarchontoglires and Laurasiatheria belonging to the Boreoeutheria (91-93). Search of Vγ9 
and Vδ2 genes across mammalian database revealed that afrotherian species, namely african 
elephant, manatee and cape golden mole carried only Vδ2 gene but not Vγ9. Still Vδ2 genes 
found in these species are highly homologous to human Vδ2 gene sequence with at least 77% 
identity and 93% sequence coverage. (Table I). Whereas both Vγ9 and Vδ2 genes are 
preserved in species (armadillo and sloth) belonging to the order Cingulata (Table 1). 
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Table I: Distribution of Vγ9, Vδ2 and BTN3-ED genes among placental mammals 
Super
Order 
 
Clade  
 
Order Family  
 
  Species  Vγ9 
(Identity/ 
Cover %) 
Vδ2 
(Identity/
Cover %) 
BTN3-ED 
(Identity/ 
Cover %) 
Afro-
theria 
Afro-
insecti-
philia 
 
Afro-
soricida 
Tenrecidae Echinops telfari  
(The Lesser hedgehog tenrec) 
- - - 
Chryso-
cloridae 
Chrysochloris asiatica (Cape 
golden mole) 
 77/96% - 
Paen-
ungulata 
 
Hyra-
coidea 
Procaviidae Procavia capensis (Rock 
hyrax) 
- - - 
Probo-
scidea 
Elephan-
tidae 
Loxodonta Africana  
(African elephant) 
- 79/96% - 
Sirinia Triche-
chidae 
Trichechus manatus 
latirostris (The Florida 
manatee ) 
- 77/93% - 
Xenar-
thra 
 
 Cingulata Dasypodi-
dae 
Dasypus novemcinctus 
(Nine-banded armadillo) * 
80/98% 77/98% 74/67% 
Pilosa Megalony-
chidae 
Choleopus hoffmanni (Sloth) 
* 
82/99% 75/95% 84/78% 
Euar-
chonto
-glires 
 
Euarchon
to 
 
Scanden-
tia 
Tupaiidae Tupaia belangeri (The 
northern treeshrew) 
- 
 
74/94% - 
Primata Cheiro-
galeidae 
Microcebus murinus 
(Grey mouse lemur) * 
81/99% 81/99% 87/100% 
Dauben-
toniidae 
Daubentonia 
madagascariensis  
(Aye-aye) * 
83/99% 83/98% 89/86% 
Tarsiidae Tarsius syrichta (Phillipine 
tarsier) 
81/99% ? 88/100% 
Hominidae Homo sapiens (Human) * 100% 100% 100% 
Glires Lago-
morpha 
Ocho-
tonidae 
Ochotona princeps (The 
America Pika) 
- - - 
Leporidae Oryctolagus cuniculus (The 
European Rabbit) 
- - - 
Rodentia Caviidae Cavia porcellus (Guinea pig) - - - 
Hetero-
myidae 
Dipodomy ordii (Kangaroo 
rat) 
- - - 
Muridae Mus musculus (Mouse) - - - 
Rattus norvegicus (Rat) - - - 
Sciuridae Spermophilis 
tridecemlineatus (Thirteen 
lined Squirrel) 
77/99% ? 83/96% 
Laur-
asia-
theria 
 
Euli-
potyphla 
 
Erinaceo-
morpha 
Erinaceidae Erinaceus europaeus 
(European hedgehog) 
- - - 
Sorico-
morpha 
Soricidae Sorex araneus (Common 
Shrew) 
- - - 
Talpidae Condylura cristata (Star nose 
mole) 
- 73/95% - 
Scroti-
fera 
Artio-
dactyla  
 
Camelidae Vicugna pacos (Alpaca) * 78/98% 75/95% 84/99% 
Camelus ferus (Wild Bactrian 
Camel) 
78/98% 73/96% 82/99% 
Camelus dromedarius 
(Dromedary) 
78/98% ? 84/99% 
Bovidae Bos taurus (Cow) 80/98% 77/93% 81/95% 
Ovis aries (Sheep) 75/98% 77/95% 79/81% 
Capra hircus (Yunnan black 76/98% 77/95% 79/78% 
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goat) 
Pantholops hodgsonii 
(Tibetan antelope) 
77/98% 77/95% 80/78% 
Suidae Sus scrofa (Wild Boar) 73/98% 79/93% - 
Cetacea Delphini-
dae 
Tursiops truncates  
(Bottle nose Dolphin) * 
79/98% 83/94% 84/99% 
Orcinus orca (Killer whales) 
* 
80/98% 83/93% 81/100% 
Chiroptera Ptero-
podidae 
Pteropus vampyrus (Flying 
Fox) 
77/97% 79/95% - 
Vespertilio
-nidae 
Myotis lucifugus (Fruit bat) - 78/98% 80/96% 
Myotis davidii (David’s 
mouse eared bat) 
- 79/98% 78/96% 
Eptesicus fuscus (Big brown 
bat) 
- 77/98% 80/96% 
Perissodac
tyla 
Equidae Equus caballus (Horse) * 80/99% 82/95% 83/99% 
Rhinocero-
tidae 
Ceratotherium simum (White 
Rhino) 
77/99% 81/95% 81/97% 
Carnivora Felidae Felis catus (Cat) - 79/80% - 
Canidae Canis familaiaris (Dog) - - - 
 
The table represents the distribution of Vγ9, Vδ2 and BTN3-ED genes across the mammals belonging to each 
superorders (92). Human genes were taken as query and blasted against the NCBI whole genome database 
(Whole-genome Shotgun database). The homologous nucleotide sequences from different species were 
indicated by the percentage of identity and sequence coverage length to that of query sequences. Asterisk 
represents the species which carries translatable Vγ9, Vδ2 and translatable BTN3-ED genes. Question mark 
represents doubt over the absence of gene. Underlined species indicate those which carry non-translatable gene 
sequences and their corresponding gene/genes were also underlined. Accession numbers of the genomic 
sequences retrieved from the database are mentioned in the materials section. 
 
Boroeutheria splits into Euarchotoglires and Laurasiatheria. Euarchotoglires is divided into 
the clade Euarchonto and Glires. Order Primata belonging to the clade Euarchonto comprises 
species which carry both Vγ9 and Vδ2 genes. Having said that the higher primates were 
earlier reported for the presence of PAg responsive Vγ9Vδ2 T cells (60, 65, 67), we searched 
for these genes in lower primates as well. Our results shows that these genes are preserved by 
lower and higher primates (Fig 6) indicating that these genes are conserved throughout the 
primate lineage with exception of Tarsius syrichata (Tarsidia) which lacks the Vδ2 gene. It is 
aimed to test whether this is due to incomplete information in the database, which is 
conceivable given the low degree of coverage of the genome (twofold), or indeed a lacking 
gene. 
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Figure 6: Conservation of Vγ9 and Vδ2 sequence among primates 
The figure represents the ClustalW2 alignment of amino acid sequences of human Vγ9 and Vδ2 sequences with 
Vγ9 and Vδ2 like sequences of primates. Genomic human Vγ9 and Vδ2 sequences and their respective genomic 
homologous sequences of primates were translated in-silico using ExPASy Translate tool. AGMonkey – African 
green monkey sequences were amplified from its PBMC. Underlined amino acids represent CDR1 and CDR2 of 
V genes adapted from published crystal structure of human G115 Vγ9Vδ2 TCR (94). The dot represents identity 
to human sequence and dash indicates gap introduced by the tool for alignment.  
 
Compared to Euarchonto, the clade Glires is in striking  contrast with regard to conservation 
of Vγ9 and Vδ2 genes because most of the families but not all belonging to the clade Glires 
are negative for these genes. Most representatives of Rodentia and Lagomorpha lack all three 
genes which correlate well with the lack of reports on PAg T cells in mouse, rats, hamsters 
and guinea pigs which are classical animal models. An interesting exception might be 
Spermophilis tridecemlineatus representing the family of Sciuridae which lacks the Vδ2 gene 
but contains translatable Vγ9 and BTN3-ED genes. 
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Figure 7: Conservation of Vγ9 sequence among mammals other than simian Primates 
ClustalW2 amino acid sequences alignment of human Vγ9 with their respective homologous V segments in 
several species which carry Vγ9 like sequence. The sequences were retrieved from the NCBI genomic database. 
a) Species which carry Vγ9 and Vδ2 like sequences b) Species which carry only Vγ9 like sequences. C) 
Alignment indicating presence of stop codon in cow Vγ9 like sequence. Underlined amino acids represent 
CDR1 and CDR2 of V genes adapted from published crystal structure of human G115 Vγ9Vδ2 TCR (94). 
Asterisk represents identity to human sequence, dot represents similarity, plus indicating stop codons, black 
highlighted fonts represents Ig domain disturbing mutations and dash indicates gap introduced by the tool for 
alignment. 
 
We also observed a similar pattern of distribution in Laurasiatheria super order, which splits 
in Eulipotyphyla and Scrotifera. Vγ9 and Vδ2 gene sequences were present in species 
belonging to Eulipotyphyla but they are absent in nearly all the species of Scrotifera. The 
above observations clearly suggest that these genes are not universally conserved among 
placental mammals though they are distributed across them . Another striking feature about 
Vγ9 and Vδ2 genes are that they are highly conserved among distinct species. Since primates 
are phylogenetically close, it is very well possible to have such a high degree of homology 
(>80% identity).  But even phylogenetically distinct species also share high degree of 
homology to human Vγ9 and Vδ2 genes. For example, Sloth and whales are quite distinct 
from each other and from humans, but still they share >75% similarity at amino acid level 
(Table 1, Fig 7 and 8).  
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Figure 8: Conservation of Vδ2 sequence among mammals other than simian Primates 
ClustalW2 amino acid sequences alignment of human Vδ2 with their respective homologous V segments in 
several species which Vδ2 like sequence. The sequences were retrieved from the NCBI genomic database. a) . 
Species which carry Vγ9 and Vδ2 like sequences. b) Species which carry only Vδ2 like sequence. Underlined 
amino acids represent CDR1 and CDR2 of V genes adapted from the published crystal structure of human G115 
Vγ9Vδ2 TCR (94). Asterisk represents identity to human sequence, dot represents similarity, black highlighted 
fonts represents Ig domain disturbing mutations and dash indicates gap introduced by the tool for alignment.  
 
Collectively, our genomic database search reveals that Vγ9 and Vδ2 genes are not restricted 
to primates and they are conserved in distinct species as well. Compared to Vγ9, Vδ2 gene 
has been preserved by more species (Fig 9). However, Vγ9 gene sequences are relatively 
more conserved than that of Vδ2 genes. Even though these genes are preserved by distinct 
species they share high homology which is evident from the phylogenetic tree where all these 
species emerge from a common root which had diverged from an outlier (Fig 9). Another 
interesting revelation is an indication for the functional association between Vγ9 and Vδ2 
genes as suggested by the observation that those species which carry Vγ9 possess Vδ2 gene 
as well. This suggests that these gene products are preserved to carry out certain functions 
(Table1). 
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Figure 9: Phylogeny of Vγ9, Vδ2 and BTN3-ED among mammals excluding simian primates  
The above tree represents phylogeny of Vγ9, Vδ2 and BTN3-ED among the non simian primates. Human Vγ9, 
Vδ2 and BTN3A1-ED and their respective homologous nucleotide sequences in several species obtained from 
genomic database were taken for the construction of a phylogenetic tree. The tree was constructed using MEGA 
5.2 software with neighbor-joining algorithm 10000 bootstrap replications and stats less than 60 were hidden. 
HuVG2, HuVG3 – were human Vgamma1 and Vgamma3 respectively; HuVD1, HuVD3 – were human Vdelta1 
and Vdelta3 respectively according to IMGT nomenclature. HuVG2, HuVG3, HuVD1, HuVD3 and Skint1 of 
mouse were used as outlier for Vγ9, Vδ2 and BTN3 phylogenetic tree construction, respectively. a) Phylogeny 
of Vγ9; b) Phylogeny of Vδ2; c) Phylogeny of BTN3-ED. 
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3.1.2 Coevolution of Vγ9, Vδ2 and BTN3 genes 
Identification of molecules involved in PAg presentation to Vγ9Vδ2 T cells has been a long 
time quest for the scientific community. In 2010 Harly C et al. has identified a molecule 
named BTN3A1 as a mandatory element for PAg mediated activation of Vγ9Vδ2 T cells 
(68). It belongs of butyrophilin family of protein. Since BTN3 is associated with the 
functionality of Vγ9Vδ2 T cells in human, we tried to investigate the evolutionary association 
between Vγ9 and Vδ2 genes and the gene of putative antigen presenting molecule. BTN3 
exists in three isoforms all sharing a highly homologous (>95% amino acid identity) 
extracellular domain (BTN3-ED) which is composed of IgV and IgC domain (95), but differ 
by featuring the intracellular B30.2 domain. We performed genomic database search across 
mammals for BTN3-ED gene sequence because species which are absent for BTN3 possess 
proteins with a B30.2 domain.  
Surprisingly like Vγ9 and Vδ2 genes, BTN3-ED is absent in pre-eutherian species. Several 
eutherian species belonging to either of eutherian magnorders possess BTN3-ED, but not all. 
This clearly indicates that BTN3-ED also emerged and evolved along with the origin of 
placental mammals. The most interesting observation was that those species that were 
negative for Vγ9 and Vδ2 were negative for BTN3 gene as well. 11 species from 10 different 
families have lost all three genes completely (Table 1). It implies a strong functional 
association between Vγ9 and Vδ2 genes and BTN3 and also indicates that these three genes 
might have coevolved along with evolution of placental mammals. 
Though several distinct species possess Vγ9, Vδ2 and BTN3-ED genomic sequences 
homologous to human genes, it is necessary to evaluate the functional property of those 
sequences by determining the presence of open reading frame (ORF). Analysis of sequences 
for the presence of ORF by in silico translation revealed that some species possess non-
translatable genomic sequences and they are not functional anymore. Interestingly, whenever 
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a species carries functional Vγ9 and Vδ2 gene, it possesses functional BTN3-ED also. Upon 
keen examination, we found out that whenever Vγ9 gene is functional, BTN3-ED is also 
functional, which again implies a strong positive association between Vγ9 and BTN3 (Table 
1). Furthermore, the BTN3-ED gene sequence is highly homologous between primates and 
non-primate species which is evident from the phylogenetic tree (Fig 9). All these data 
suggest that Vγ9, Vδ2 and BTN3 genes emerged along with origin of placental mammals and 
indicate the functional association between Vγ9, Vδ2 and BTN3 genes.  
Since the intracellular domain of BTN3A1 has been suggested to play role in PAg mediated 
activation of T cells (68, 95), we looked at the distribution of BTN3-ID. The search revealed 
the presence of BTN3-ID like sequence in several placental species as well as monotrometa 
and marsupials (data not shown). We did not find BTN3-ID like sequences in species which 
lacked BTN3-ED sequences. Most of the species which possess BTN3-ED like sequences 
carried BTN3-ID as well and they are orthologous to human BTN3.  
After omitting the species which possess stop codons in genomic overlaps of either of Vγ9 or 
Vδ2 genes, there were 10 species from 7 families which possess Vγ9, Vδ2 and BTN3-ED in 
silico translatable sequences which were determined as functional ones. Those 8 species are: 
1. Sloth 2. Armadillo 3. Aye aye 4.Grey mouse lemur 5. Human 6. Alpaca 7. Wild Bactrian 
camel 8. Bottle nose dolphin 9. Killer whales and 10. Horse. Clustal alignment of Vγ9 and 
Vδ2 protein sequences indicate that these sequences were very well conserved among these 
species (Fig 7a and Fig 8a). Especially the conservation at protein level was evident from 
Vγ9 sequence (Fig 7a). The conservation of quality of genes may be vital to preserve the 
response against PAg or PAg like antigens. However, deduced amino acid sequences of horse 
Vγ9 and Vδ2 gene sequences show that they possess substitution mutations replacing 
conserved cysteines which disturb the Ig domain of these genes. This may lead to loss of 
function in horse. We also found no transcripts of Vγ9 and Vδ2 containing TCR-chains from 
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its PBMC (data not shown) and therefore neglected horse for further analysis. Hence, we 
constructed a phylogenetic tree for Vγ9, Vδ2 and BTN3-ED for rest of the species (Fig 10) 
and by use of an outlier it became obvious that all those sequences are homologous.  
 
Figure 10: Co-evolution of Vγ9, Vδ2 and BTN3 sequences among double positive species 
a) The figure represents phylogeny of Vγ9, Vδ2 and BTN3-ED (extracellular domain) for 9 species which 
possess all three in silico translatable genes. Human Vγ9, Vδ2 and BTN3-ED and their respective homologous 
nucleotide sequences in these species obtained from genomic database were taken for the construction of a 
phylogenetic tree. The tree was constructed using MEGA 5.2 software by maximum likelihood algorithm with 
10000 bootstrap replications and stats less than 60 were hidden. HuVG2, HuVG3 – were human Vgamma1 and 
Vgamma3 respectively; HuVD1, HuVD3 – were human Vdelta1 and Vdelta3 respectively according to IMGT 
nomenclature. HuVG2, HuVG3, HuVD1, HuVD3 Skint1 of mouse were used as outlier for Vγ9, Vδ2 and BTN3 
phylogenetic tree construction, respectively. Accession numbers of the sequences retrieved from the database 
are mentioned in materials section. b) Representation of phylogeny as unrooted tree and stats frequency were 
hidden. 
 
Construction of phylogenetic un-rooted tree has validated that all gene sequences are 
homologous indicated by the formation of clustering of species distinct from an outlier. The 
phylogenetic trees were constructed using different methods namely maximum likelihood, 
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neighbor joining and minimum evolution, but all the trees looks similar with comparable 
statistical frequencies (data not shown). Considering all the above data, it is evident that all 
three genes; Vγ9, Vδ2 and BTN3-ED have coevolved along with placental mammals. The 
quality of sequence is conserved among closely related species as well as distinct species, 
which strongly indicates the necessity of preservation of quality to maintain TCR-ligand like 
functional relationship and suggests that it might be under the control of the three genes.   
 
3.1.3 Alpaca Vγ9 recombines preferentially with JP segment 
Eight non-primate species are probable carriers of Vγ9 and Vδ2 genes. Only for alpaca we 
had access to lymphoid cells (PBMC) which may contain Vγ9Vδ2-TCR expressing cells. The 
homology of alpaca and human Vγ9 and Vδ2 genes (Fig 11a and Fig 12a) allowed the search 
for rearranged and expressed Vγ9-γ and Vδ2-δ TCR chains. We obtained PBMC from two 
animals and amplified Vγ9 and Vδ2 chains from cDNA from both the animals to analyze 
VDJ recombination and features which are typical PAg responsive Vγ9 and Vδ2 chains of 
human. Partial length Vγ9 and Vδ2 chains, comprising complete V segment and partial C 
segment were amplified using Taq DNA polymerases and analyzed by TA cloning.  
Analysis of alpaca partial length Vγ9 (V-C) chains revealed that different Jγ segment 
recombines with alpaca Vγ9 chain (Fig 11 and Table II). Interestingly, among different Jγ 
segments human JP like segment also found to be recombined with Vγ9 in alpaca. Even 
though, Vγ9 chains with different Jγ segment exists in alpaca, the frequency of Vγ9-JP 
recombined Vγ9 chain was more than that of other Vγ9-J recombination. Out of 34 clones 
analyzed 24 clones are unique based on their unique CDR3 nucleotide sequences. Sequencing 
of Vγ9 chains of 34 clones revealed 20 clones carry a fully translatable Vγ9 chain. 
Surprisingly, 18 (13 unique) out of those 20 (14 unique) clones carry Vγ9-JP recombined 
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Vγ9 chain (Fig 11a). This strongly suggests the preference towards the selection of Vγ9 chain 
with Vγ9-JP recombination in alpaca. 
Table II: Vγ9J recombination found in alpaca 
 
 
 
 
 
 
 
 
The table represents the usage of different J segment by alpaca Vγ9 chains. The partial length alpaca Vγ9Cγ 
chain was amplified and analyzed by TA cloning. Sequencing reveals 20 out of these 34 TA clones contains 
VDJ recombined Vγ9 chains without any stop codons. The table indicates the proportion of translatable and 
non-translatable Vγ9 chains for each J segment.  
 
From the analysis of TA clones with alpaca Vγ9 chains, we also found the existence of a 
polymorphism in a JP like segment. We found three different JP like segments, which are 
provisionally assigned as JPA, JPB and JPC as we are were unable to define them as three 
genes or alleles (Fig 11b). From the genomic database, we could retrieve a sequence only for 
VpJPA (Accession number - GB|ABRR02020993.1) and not for other two forms of JP 
segment. In animal 1 we identified VpJPA and B and in animal 2 VpJPB and C were 
identified. By alanine scanning mutagenesis, germ line encoded lysine residues K (1-3) of 
human JP (Jγ1.2) were identified as important for the PAg reactive Vγ9+ T cell clones in 
humans (67). K3 was reported as essential for the pairing of Vγ9 with Vδ2 chain which was 
100% conserved in all JP segments of alpaca (Fig 11b). K1 and K2 were reported to be 
important for PAg reactivity and K1 was conserved or replaced by arginine ‘R’ which is 
similar to lysine (basic residue) in alpaca. In place of K2, alpaca JP segments carry a neutral 
Type of Jγ in sequenced clones  No. of clones (34) 
Translatable (20) Non-translatable (14) 
DGRTIKVFGSGTRLIVT (Genomic) 
DGRTIKVFGSGTRLIIT (JP)  
 
14 
 
4 
DGKTIKVFGSGTRLIIT (JP) 4 4 
HRVFDGGTKLIVT (JP1)  2 1 
WIKIFGEGTKLIVIPP (JP2, mouse J4)  - 4 
WATTIKVFGSGTRLIIT (J1)  - 1 
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charged threonine ‘T’ amino acid (Fig 11b). In summary, alpaca JP segment was very much 
similar to JP segment of γ-chain found in PAg responsive human Vγ9Vδ2 T cells.  
 
Figure 11: Characterization of Alpaca Vγ9 chains 
a) Alignment of VJ recombination sequences found in TA clones bearing VDJ recombined, translatable partial 
length Vγ9Cγ chain. Alignment 1-13 represents Vγ9 JP recombination with different CDR3 sequences and 
sequence 14 represents a Vγ9 JP1 recombination found in translatable sequences. TA clones named as VpGam 
(clone no) and were generated in a single experiment with PBMC of animal 2. b) The figure represents 
polymorphism observed in JP like segments found in alpaca PBMC (HuJP – Human JP, JP – Alpaca JP). JPA, 
JPB and JPC were different copies of JP like J segments. JPA and JPB were found in full length chains 
amplified from animal1 and JPB and JPC were found in partial length chains amplified from animal 2. Bold 
fonts in human JP segments were important residues necessary for PAg recognition. 
 
3.1.4 Hydrophobic residue at δ97 and diverse CDR3δ length in alpaca Vδ2 chain 
Similar to alpaca Vγ9 analysis, partial length Vδ2 chains comprising complete V and partial 
length (V-C) were amplified and cloned into TA vector. Twenty five TA clones carrying 
partial length Vδ2-TCRδ chains were analyzed by sequencing to characterize the features of 
alpaca Vδ2 chain. Seventeen out of 25 Vδ2-TCRδ specific clones were VDJ rearranged and 
translatable without any stop codons (Fig 12). The salient feature of PAg responsive human 
Vδ2 chain is the acquisition of aliphatic hydrophobic amino acid like leucine, isoleucine, 
valine and glycine at position δ97 (94, 96). Analysis of VDJ rearranged translatable alpaca 
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Vδ2 reveals the presence of such hydrophobic residues at δ97 in at least eight clones. Another 
striking similarity between human and alpaca Vδ2 chains was variability in length of CDR3δ 
(96). Like humans; alpaca possesses CDR3δ length ranging from 11-18 amino acids. Unlike 
alpaca Vγ9 chains, all VDJ rearranged Vδ2 chains carry identical Jδ segment, which is highly 
homologous to human Jδ4 (TRDJ*04) (Fig 12) 
 
Figure 12: Characterization of alpaca Vδ2 chain  
The alignment represents the CDR3 amino acid sequence of Vδ2 clones with unique CDR3 sequence. The 
partial length alpaca Vδ2 chain was amplified and analyzed by TA cloning. Sequencing reveals 17 out of these 
25 TA clones contains VDJ recombined Vδ2 chains without any stop codons. Of those 17 clones, 15 carry 
different CDR3 nucleotide sequences. TA-clones named as VpDel (clone no). Bold fonts indicate residues I, L, 
V and G which are conserved by PAg responsive human Vδ2 chains. Clones were generated in a single 
experiment using PBMC of animal 2. 
 
Since we observed the presence of non-translatable VDJ rearranged Vγ9 and Vδ2 chains 
amplified from cDNA of alpaca PBMC, we tested the significance of such an event by 
analyzing the cDNA of human PBMC. Similar to alpaca, we were also able to find the 
presence of non-translatable VDJ rearranged Vγ9 and Vδ2 chains in human cDNA (data not 
shown). 
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3.1.5 Cloning of alpaca Vγ9 and Vδ2 like chains  
The analysis of partial length Vγ9 and Vδ2 reveals striking similarities towards to PAg 
responsive human Vγ9 and Vδ2 TCR chains. Hence, we aimed to amplify full length Vγ9 and 
Vδ2 TCR-chains in order to clone and express them, and to examine their ability to pair and 
form a TCR at the cell surface. Since the complete sequence of Cγ and Cδ were unavailable 
at NCBI database, we performed 3’RACE PCR to amplify the unknown cDNA ends of Cγ 
and Cδ. As a result, we managed to obtain complete sequence information of Vγ9 and Vδ2 
TCR chains expressed in PBMC. Thereafter, VDJ rearranged full length Vγ9 and Vδ2 TCR 
chains of alpaca were amplified from cDNA and were cloned into pEGZ and pIH vectors, 
respectively. pEGZ and pIH carried green fluorescent protein and mammalian selection 
markers respectively, which allowed us to track and select cells transduced with those genes 
of interest. The cloned TCR chains were sequenced and the alignment of alpaca Vγ9 (VpVγ9; 
GenBank accession number - KF734082) and Vδ2(VpVδ2) with human Vγ9Vδ2 G115 TCR 
clearly indicates the partial conservation of human PAg reactive features (94, 96) in alpaca 
TCR chains. Full length VpVγ9 possesses Vγ9JP recombination (Fig 13) which is mandatory 
for the PAg recognition. For analysis of alpaca chains to form TCR, we chose two alpaca 
Vδ2 (GenBank accession number - KF734083 and KF734084) which carry leucine (L) and 
glycine (G) as aliphatic hydrophobic residue at position δ97 (Fig 13) which is required for 
PAg reactive human Vδ2 TCR chain (94, 96). Collectively, analysis of full length Vγ9 and 
Vδ2 chains of alpaca reveals that they share high similarity towards human Vγ9 and Vδ2. 
They also carry human PAg responsive Vγ9 and Vδ2 like features which indicate a high 
likelihood of alpaca Vγ9 and Vδ2 TCR chains to exhibit PAg reactivity. 
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Figure 13: Alignment of alpaca Vγ9 and Vδ2 chain with human G115 Vγ9Vδ2 TCR 
VpVγ9 and VpVδ2G/VpVδ2L are Vγ9 and Vδ2 chains amplified from alpaca PBMC. Alpaca Vγ9 and Vδ2 
chains are aligned with human G115 γδ TCR chains. Bold fonts with asterisk - the germline encoded lysine ‘K’ 
residues in CDR3 of human Vγ9; black highlighted italics – hydrophobic residues at δ97 of Vδ2 chain. VpVδ2G 
and VpVδ2L are two alpaca Vδ2 chains which carry glycine ‘G’ and leucine ‘L’ at δ97 position. CDRs of Vγ9 
and Vδ2 chains are underlined and are adapted from published crystal structure of human G115 Vγ9Vδ2 TCR 
(94). Accession numbers of full length chains are VpVγ9- KF734082; VpVδ2G - KF734083; VpVδ2L- 
KF734084 Clones were generated from PBMC of animal 1.  
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3.1.6 Expression of alpaca Vγ9Vδ2 TCR 
As the sequence analysis of alpaca full length Vγ9 and Vδ2 were promising, we proceeded to 
test their ability to form functional TCR. To achieve the same, we transduced alpaca Vγ9 and 
Vδ2 chains into TCR negative mouse T cell hybridomas (Fig 14). The alpaca Vγ9(VpVγ9) 
was co-expressed with either of alpaca Vδ2 chains (VpVδ2G and VpVδ2L). The expression 
of alpaca Vγ9Vδ2 TCR was analyzed by staining with mouse CD3ε, which is expected to be 
expressed at the cell surface if alpaca Vγ9Vδ2 TCR chains are pairing and become associated 
with the mouse CD3 complex.  Figure 14a shows that this was the case. The functionality of 
the TCR was assessed by its ability to produce IL-2 upon CD3 crosslinking. The activation of 
either of the alpaca Vγ9Vδ2 TCR complex (Vγ9Vδ2L TCR and Vγ9Vδ2G TCR) by CD3 
crosslinking resulted in production of IL-2 which confirmed that alpaca Vγ9 and Vδ2 TCR 
chains can pair together to form a functional TCR (Fig 14b). In order to analyze the 
compatibility between distinct human and alpaca TCR chains, human Vγ9 and alpaca Vδ2 
TCR chains as well as alpaca Vγ9 and human Vδ2 TCR chains were transduced. We 
observed surface expression of TCR in cells transduced with human Vγ9 and alpaca Vδ2 
TCR chains, but not in the case of alpaca Vγ9 and human Vδ2 TCR transductants (data not 
shown). The above result suggests that these two species share a degree of compatibility 
between them to form chimeric Vγ9Vδ2 TCR. Since alpaca Vγ9 and Vδ2 TCR formed 
functional TCR, we accessed the possibility of existence of PAg reactive T cells in alpaca 
PBMC. So we performed a preliminary experiment where alpaca PBMC was cultured with 
HMBPP and agonist BTN3 antibody (mAb 20.1) for 24 hours. We did not observe any 
activation/proliferation of cells in PAg cultured PBMC, but observed the activation of cells in 
one of two culture-plate wells treated with agonist (mAb 20.1) antibody (data not shown).  
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Figure 14: Alpaca Vγ9 and Vδ2 chains form functional TCR  
a) Surface expression of alpaca Vγ9Vδ2TCR in BW58 r/mCD28. Histogram represents CD3 expression on the 
surface of cells transduced with Vγ9 and Vδ2 chains. Solid black - unstained cells, solid tinted lines - isotype 
staining. Solid and dashed lines represent the anti-CD3 staining of cells transduced with different Vγ9 and Vδ2 
chains. Black line – human γδ TCR; grey line - Vp TCR D97G (Alpaca γδ TCR, δ97G), dashed line – Vp TCR 
D97L (alpaca γδ TCR, δ97L). b) IL2 production by BW58c r/mCD28 Vγ9Vδ2 TCR transductants: Human - 
Human γδ TCR; V.p G – Vp TCR δ97G, V.p L – Vp TCR δ97L. Error bar indicates standard deviations 
recorded in three individual experiments. IL-2 concentration indicated by pg/mL and anti-CD3 antibody 
concentration used for assay indicated in microgram/mL. 
 
3.1.7 Predicted PAg binding sites of human BTN3A1 are conserved in alpaca BTN3-
ED 
The exact mechanism behind PAg presentation to Vγ9Vδ2 TCR still remains unclear, but in 
the last two years, BTN3A1 has been proven to be mandatory for the presentation of PAg and 
PAg mediated activation of Vγ9Vδ2 T cells (66, 68, 71). BTN3A1 comprises of extracellular 
domain (IgV-IgC) and intracellular B30.2 domain. Recently, Vavassori et al. work suggested 
the role of  BTN3A1 as antigen presenting molecule to which PAg binds to its extracellular 
domain (BTN3-ED) (71). Hence, we searched for the presence of human BTN3-ED like 
sequence in alpaca genomic sequence. Since we retrieved such a sequence from alpaca 
genomic database, we tried to retrieve the complete sequence for alpaca BTN3 sequence. But 
we were not able to retrieve a complete sequence from the database, especially the leader 
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sequence which is necessary for the localization of the mature protein. So we performed 
5’RACE PCR to amplify unknown cDNA ends and managed to identify the 5’end sequence. 
Further, we amplified the complete alpaca BTN3 like sequence comprising BTN3-ED as well 
as intracellular B30.2 domain. Since BTN3-ED was believed to the binding site of PAg, we 
analyzed the alpaca sequence by aligning with human BTN3-ED. Interestingly, the amino 
acids which are predicted as the binding site for PAg in human BTN3-ED were completely 
conserved in alpaca (Fig 15). Above results suggests the presence of PAg interactive human 
BTN3A1 like protein in alpaca suggesting the possibility for the existence of PAg responsive 
Vγ9Vδ2 T cell population in alpaca as well. 
 
Figure 15: Sequence alignment of human BTN3A1 and alpaca BTN3 
The figure represents alignment of human BTN3A1 (HsBTN3A1) with its homologue found in alpaca 
(VpBTN). Bold and underlined residues of human BTN3A1 ED contribute to hydrogen bond interactions and 
van der Waals interactions with PAg (71). The dots represent identity to the human sequence; dash represents 
gaps introduced for alignments. Domain of the corresponding amino acids was mentioned above the sequence. 
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3.1.8 Alpaca Vγ9 and Vδ2 TCR lack Somatic hyper-mutation 
Recent studies on Camelus dromedarius (the dromedary) reported the presence of somatic 
hypermutation (SHM) in γδ TCR-chains comprising Vγ and Vδ genes other than Vγ9 and 
Vδ2 (97, 98). Since alpaca is phylogenetically very close to the dromedary, it was of interest 
to look for SHM in Vγ9 and Vδ2 like genes of alpaca. The frequencies of mutations we 
observed in V genes of Vγ9 and Vδ2 TCR-chains are negligible and were equivalent to the 
frequencies observed in C segments of Vγ9 and Vδ2 chains (Table III). We conclude that 
Vγ9 and Vδ2 TCR-chains of alpaca lack SHM. Though alpaca Vγ9 and Vδ2 genes lack 
SHM, we took the effort to characterize other Vγ and Vδ genes which are reported to possess 
SHM in dromedary. Those genes are TRGV1, TRGV2, TRDV1, TRDV2 and TRDV4 and 
analysis of these genes revealed that TRDV1 and TRDV4 possess mutations but not the rest 
of the V genes (Table IV). But further analysis of database sequence of dromedary revealed 
the presence of several homologues for TRDV1 and TRDV4, which carry slight variations 
between them at nucleotide level. Moreover, comparison of available genomic sequences of 
TRDV1 and TRDV4 with cDNA clones indicated that those cDNA sequences carry 
mutations. The above results suggest the possible presence of SHM in TRDV1 and TRDV4 
of alpaca and also the presence of duplicated genes. Therefore, in-depth investigations are 
required to validate whether mutations observed in TRDV1 and TRDV4 are somatic hyper-
mutations or if they are a result of duplication events, because presence of enormous 
duplication events in TCRG and TCRD locus of ruminant have been previously reported (99-
101). 
Table III: Absence of somatic hypermutation in Vγ9 and Vδ2 chains of alpaca 
Chain Clones 
analyzed  
Total no 
of  bases 
Mutations 
observed 
Mutation 
Frequency 
V gene of Vγ9 chain 34 9996 11 1.1*10-3 
C segment of Vγ9 chain 34 8432 9 1.1*10-3 
V gene of Vδ2 chain 25 7000 7 1.0*10-3 
C segment of Vδ2 chain 25 9675 17 1.7*10-3 
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The table represents the frequency of mutations observed in V gene and C segment of Vγ9 and Vδ2 chain of 
alpaca. 
Table IV: Search for somatic hypermutation in other V genes of γ and δ TCR genes of alpaca 
Chain Clones 
analyzed  
Total no 
of  bases 
Mutations 
observed 
Mutation 
Frequency 
TRDV1 2 559 17 3/100 bases 
C segment of D  610 NIL NIL 
TRDV2 3 837 NIL NIL 
C segment of D  810 NIL NIL 
TRDV4 3 864 13 1/100 
C segment of D  825 NIL NIL 
TRGV1 3 777 NIL NIL 
C segment of GV1  720 NIL NIL 
TRGV2 3 927 NIL NIL 
C segment of GV2  825 NIL NIL 
The table represents the frequency of mutations observed in V gene and C segment of Vδ1, Vδ2, Vδ4, Vγ1 and 
Vγ2 chain of alpaca.  
 
3.1.9 Vγ9 and Vδ2 chains are homologous between human and African green monkey 
(AGM) 
The presence of PAg responsive Vγ9Vδ2 T cell population in African green monkeys was 
earlier reported (60), but sequences of Vγ9Vδ2 TCRs of AGM were not known. Interestingly, 
it was also found that COS-7 cells derived from AGM were unable to activate human 
Vγ9Vδ2 T cells (96). This raised question over the chances for the existence of species 
specificity in regard to PAg presentation and activation of T cells within primate lineage. 
Hence, cloning and testing AGM Vγ9Vδ2 TCRs will yield interesting data to understand 
more on species specificity with regard to PAg presentation. From mRNA of AGM, we 
amplified Vγ9 and Vδ2 chains. They both share a high degree of similarity towards human 
Vγ9 and Vδ2 chains. Like in humans, AGM Vγ9 chains do possess Vγ9 recombined JP 
segment which is typical feature for PAg reactive human Vγ9Vδ2 T cells. Similarly in case 
of Vδ2 chains, conservation of aliphatic hydrophilic amino acid at δ97 is mandatory for PAg 
reactivity and this feature has been conserved in the AGM Vδ2 chain as well (Fig 16). So at 
sequence level, AGM Vγ9 and Vδ2 chains that carry all significant features which contribute 
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to PAg recognition has been well preserved. Hence, AGM TCR can be tested for their ability 
to recognize PAg cross presented by human antigen presenting cells. 
 
Figure 16: Sequences of AGM Vγ9 and Vδ2 TCR chains  
AGMVγ9 and AGMVδ2G are Vγ9 and Vδ2 chains amplified from African green monkey PBMC. AGM Vγ9 
and Vδ2 chains align with human G115 γδ TCR chains. Bold fonts with asterisks - the germline encoded lysine 
‘K’ residues in CDR3 of human Vγ9; black highlighted bold italic font – hydrophobic residues at δ97 of Vδ2 
chain. CDRs of Vγ9 and Vδ2 chains are underlined and are adapted from the published crystal structure of 
human G115 Vγ9Vδ2 TCR (94). 
 
3.1.10 Interspecies interaction between human and AGM 
Since it was earlier reported that COS cells were not able to activate human Vγ9Vδ2 TCR, 
we made an attempt to examine the ability of COS cells in presenting PAg to human and 
AGM Vγ9Vδ2 TCR. So we transduced COS cells with rat CD80 (rCD80) gene for proper 
signaling of co-stimulation required for the activation of our reporter Vγ9Vδ2 TCR 
Results 
55 
 
transductants in presence of PAg. We found that COS rCD80 cells were able to present PAg 
to human and AGM Vγ9Vδ2 TCR transductants (Fig 17a), but they were unable to present 
PAg as good as RAJI cells to human Vγ9Vδ2 TCRs. AGM Vγ9Vδ2 TCRs show auto-
reactivity to RAJI cells even in absence of PAg. As it was well established that BTN3 is 
mandatory for PAg presentation, from our results we can conclude the BTN3 (endogenous) 
of COS cells can present PAg to human TCR. Interestingly, human BTN3 transduced COS 
cells activated both human and AGM Vγ9Vδ2 TCR several fold stronger than untransduced 
COS cells (Fig 17b). Hence it is evident that human BTN3 can very well present PAg to 
AGM Vγ9Vδ2 TCR and COS BTN3 can present to human Vγ9Vδ2 TCR (Fig 17a). From the 
above results, we conclude that AGM and Human can cross present PAg and activate 
Vγ9Vδ2 TCR of the both the species. 
 
Figure 17: Cross species interaction between human and AGM 
a) COS cells transduced with and without human BTN3A1 were tested for their ability to activate Human and 
AGM Vγ9Vδ2 TCR transductants in the presence of 3μM HMBPP. Raji cells were used as positive control. b) 
Represents the reactivity of AGM Vγ9Vδ2 TCR transductant to human BTN3A1 COS transductant. COS 
rCD80, COS rCD80/BTN3, RAJI and BW cells are antigen presenters in presence of 3μM HMBPP and 8mM 
SBA. RAJI and BW cells are positive and negative controls. 
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3.2 Identification of chromosome(s) involved in phosphoantigen presentation 
3.2.1 Jurkat cells and PBL for human/mouse hybrids with BW 5147 Cells 
The recognition of PAg by Vγ9Vδ2 TCR requires cell-cell contact and most of the tissues of 
human origin can present PAg to human Vγ9Vδ2 T cells (34, 57, 102). Though BTN3A1 was 
shown to be mandatory for the presentation of PAg, the exact mechanism of PAg 
presentation and other molecules involved in PAg presentation  were unknown (66, 68, 71). 
Hence, we made an attempt to identify the chromosome(s) which carry the genes necessary 
for antigen presentation by using human/mouse somatic hybridomas. Interestingly, rodents 
are suitable partners as they lack Vγ9, Vδ2 TCR and BTN3 genes, as previously shown by us 
(103) and also reported in this thesis. Therefore, they lack mechanism for PAg mediated 
presentation and activation of Vγ9Vδ2 T cells (4, 68). Human/mouse somatic hybridomas 
have a long history of having been used for mapping human genes (78, 80, 82, 104) as well 
as identification of functional human genes. Several human origin cell lines, such as  Jurkat, 
RAJI, HEK293T cells, etc. have been reported as good presenters of PAg to Vγ9Vδ2 TCRs 
(56, 68). Hence, we tried to construct hybridomas of cells of human origin in combination 
with HAT-sensitive mouse T cell hybridoma cells line (BW5417 cell line). From the above 
cell lines, we constructed stable Jurkat/BW hybridomas (J/BW). Similarly, Human peripheral 
blood lymphocytes (PBL) were also fused with BW cells and were successfully constructed 
(PBL/BW).  
 
3.2.2 Characterization of hybridomas for human and mouse markers 
Soon after HAT selection, hybridomas were tested for the expression of human (Jurkat) and 
mouse (BW) markers to ensure they were true hybridomas. The hybridomas were analyzed 
for the expression of human MHC class I, human transferrin receptor (CD71) and ratCD80. 
MHC and transferrin represents human, whereas rCD80 represent BW mouse cells because 
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BW cells were transduced with rCD80 gene. FACS staining confirmed the expression of 
hCD71, human MHC class I molecules and rCD80; and indicated that the hybridomas were 
derived from true fusion of human and mouse cells (Fig 18).  
 
Figure 18: Characterization of Jurkat/BW hybrids 
The hybridomas were characterized for the expression of human and mouse markers. Hybridomas were stained 
for a) human CD71, b) rat CD80, c) human MHC Class I. Jurkat and BW cells were used as control cell lines. 
 
3.2.3 Antigen presentation by human/mouse hybridomas 
Once the Jurkat and PBL based hybridomas were successfully constructed, we aimed to test 
their ability to present PAg. Few single cell clones which appeared after HAT/antibiotic 
selection of J/BW and PBL/BW hybridomas were tested for their ability to present PAg to 
Vγ9Vδ2 TCR transductants. The hybridomas were co-cultured with Vγ9Vδ2 TCR 
transductants in the presence of HMBPP and SBA. The stimulation clearly indicated the 
obvious differences between J/BW and PBL/BW clones in their ability to stimulate the TCR 
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transductants in the presence of antigen. Two clones of Jurkat/BW hybridomas (D3 and C6) 
(Fig 19a) and a clone (C12) of PBL/BW hybridomas (Fig 19b) were able to present HMBPP 
to Vγ9Vδ2TCR transductants. But none of them were able to activate TCRs in presence of 
SBA which already indicates the absence of compounds necessary for endogenous antigen 
presentation (Fig 19), which could be due to loss of chromosome encoding containing the 
respective genes or of expression of these genes. Though Jurkat/BW and PBL/BW hybrids 
present antigen, Jurkat/BW hybrids present relatively better which is indicated by the 
increased production of IL-2 by Vγ9Vδ2 TCR transductants (Fig 18a). Since it is known that 
loss of chromosome is a heterogeneous pattern (105), we performed single cell dilution of the 
first appeared PAg presentable hybrid clones. In summary, we proved for the first time that 
human/mouse somatic hybrids do present the PAg to Vγ9Vδ2 TCR transductants and might 
serve as a tool to map genes important for that feature.  
 
Figure 19: PAg presentation by Jurkat/BW hybrids to Vγ9Vδ2 TCR transductant  
Hybridomas were tested for their ability to present PAg to Vγ9Vδ2 TCR transductant. Hybridomas and Vγ9Vδ2 
TCR transductant were co-cultured along with HMBPP and SBA overnight. RAJI and BW cells were positive 
and negative control respectively, for the experiment. a) Analysis of Jurkat/BW clones b) Analysis of PBL/BW 
clones 
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3.2.4 Loss of chromosome by human/mouse hybridomas 
Since hybridomas were able to present PAg, we aimed to analyze the stability of human 
genomic content in J/BW hybrids and PBL/BW hybrids by PCR karyotyping using 
previously reported human chromosome specific primers (84, 85) and identified loss of 
human chromosomes by Jurkat/BW (Fig 20) and PBL/BW clones (Table V and VI). PCR 
karyotyping also revealed some interesting difference between Jurkat and PBL hybridomas. 
In general, Jurkat/BW clones relatively lost more human chromosomes than PBL/BW clones. 
Within the span of 3 months Jurkat/BW clones have lost 13 human chromosomes where 
PBL/BW clones have lost only 1 or 2 human chromosomes (Table V). It is evident that 
PBL/BW hybridomas were more stable than Jurkat/BW Hybridomas (Table V) and it further 
strengthens that Jurkat/BW hybridomas were suitable to proceed further as they show better 
activation of Vγ9Vδ2 TCR transductants in presence of PAg. 
 
Figure 20: Human chromosome PCR karyotyping of Jurkat/BW hybridomas  
Characterization of hybridomas for presence of human chromosomes. RAJI, A4 MC, A2, A11, A10 and BW is 
the order of samples analyzed. The number above the DNA samples indicates the chromosome tested for. RAJI 
and Mouse cell line ‘BW’ acts a positive and negative control for human specific primers. 
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Another interesting observation from the karyotyping analysis, especially from J/BW clones 
is the similarity within the clones with regards to preservation of human chromosomes. For 
e.g., master clone (A4) and its daughter clones (A11, A2 and A10) shares similar human 
genome content but they confer a very little degree of heterogeneity, which is indicated by 
the loss of chromosome 3 by daughter clone A2 and loss of chromosome 6 and 10 by A10, 
apart from the rest of chromosomes which are uniformly lost by master and daughter clones.  
Table V: Karyotyping analysis of Jurkat/BW and PBL/BW hybrids 
Human 
chromosomes 
Jurkat/BW Clones  PBL/BW Clones 
A4(+/+) A11(++/+) A2(++/+) A10(-/-) C6(++/-) G3(++/+) G5(++/-) 
Chr1 + + + + + + + 
Chr2 - - - - - + + 
Chr3 + + - + - + - 
Chr4 + + + + + + + 
Chr5 + + + + + + + 
Chr6 + + + - + + + 
Chr7 - - - - - + - 
Chr8 - - - - + + + 
Chr9 - - - - + + + 
Chr10 + + + - + + + 
Chr11 - - - - + - + 
Chr12 + + + + - + + 
Chr13 - - - - + - - 
Chr14 + + + + + + - 
Chr15 + + + + + + + 
Chr16 - - - - + + + 
Chr17 - - - - + + + 
Chr18 - - - - + + + 
Chr19 + + + + + + + 
Chr20 - - - - - - - 
Chr21 + + + + + + + 
Chr22 + + + + + + + 
ChrX + + + + + + + 
 
The table represents the karyotyping of Jurkat/BW (JBW) hybridomas and PBL/BW for human genomic 
content. A4MC is a master JBW clone; A2, A11 and A10 were daughter clones of A4. C6 is a master PBLBW; 
G3 and G6 were its daughter clones. The activation of Vγ9Vδ2 TCR transductants by hybridomas in presence of 
HMBPP/SBA is indicated as + or -. The nature of the human chromosome content in hybridomas was 
represented as red plus and black minus sign. Red plus indicates presence of chromosome; black minus indicates 
loss of chromosome. 
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3.2.5 Lack of chromosome 6 correlates with inability to activate TCR transductants 
Since the loss of chromosome is a random event, the hybridomas do exhibit heterogeneity in 
human chromosome content. Hence, we performed single cell dilution of hybridomas at 
regular intervals and analyzed the clones for their capacity to present PAg and for their 
genomic content. By this procedure, we found a daughter clone A10 which arose from its 
master clone A4 which was unable to stimulate the Vγ9Vδ2 TCR transductants in presence of 
HMBPP (Fig 21a). Immediate PCR karyotyping of master clone along with sub-clones and 
other antigen presentable clones revealed that the clone A10, which was unable to present 
PAg, was negative for chromosome 6 (Fig 21b). But the antigen presentable master clone A4, 
and its daughter clones A2 and A11 were positive for chromosome 6. 
 
Figure 21: Lack of chromosome 6 - unable to activate Vγ9Vδ2 TCR transductant  
a) IL-2 production by Vγ9Vδ2 TCR transductant. Jurkat/BW sub-clones along with their master clone were 
tested for their ability to present PAg to Vγ9Vδ2 TCR transductant. A4 is the master clone, A2, A11, A10 were 
its sub/daughter clones. Hybridomas and Vγ9Vδ2 TCR transductant were co-cultured along with HMBPP 
overnight. RAJI and BW cells were positive and negative control, respectively, for the experiment. b) Figure 
represents loss of chromosome 6 by a sub clone A10 of  its master clone A4. The clone A10 was not able to 
stimulate the Vγ9Vδ2 TCR transductant. RAJI, A4 MC, A2, A11, A10 and BW are the order of samples 
analyzed.  
 
Lack of chromosome 6 was the distinct difference between the clone A10 and the rest. Since 
it was already known that BTN3A1 gene is located on chromosome 6 (69) and BTN3A1 plays 
important role in PAg mediated activation of Vγ9Vδ2 T cells, one can correlate the loss of 
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function with the loss of chromosome. Thus, we correlate the presence of chromosome 6 with 
the positive nature of antigen presentation by the hybridomas and loss of BTN3 genes could 
be the reason behind the failure for the activation of Vγ9Vδ2 TCR transductants by 
chromosome 6 negative clone. Hence, our data independently validates that chromosome 6 is 
essential for the presentation of PAg (71). 
3.2.6 BTN3 is vital for PAg presentation by human/mouse hybrids 
It was earlier shown that human BTN3 plays vital role in presentation of PAg to Vγ9Vδ2 T 
cells (66, 68, 71). From the hybridomas we could infer the role of chromosome 6 in PAg 
presentation. Since BTN3 is present in chromosome 6, we validated the function of human 
BTN3 in PAg by human/mouse hybrids. We cocultured the hybrids with antagonist human 
BTN3 MAb (BT3 103.2). This resulted in inhibition of the activation of Vγ9Vδ2TCR 
transductants (Fig 22). The clones were able to activate Vγ9Vδ2 TCR to a great extent, but 
this activation was completely inhibited by the use of BT3 103.2. This again confirms the 
involvement of human BTN3 in PAg presentation and also affirms the lack of any such 
molecule in mice which could complement human BTN3 function.  
 
Figure 22: BTN3 is essential for PAg presentation property of Jurkat/BW hybridomas  
Analysis of effect of anti-BTN3 (BTN3 103.2) antibody in PAg presentation by hybridomas. Jurkat/BW sub-
clones along with their master clone were tested for their ability to activate Vγ9Vδ2 TCR transductant in the 
presence and absence of antagonist BTN3 antibody (BTN3 103.2). A4 is the master clone, A2, A11, A10 were 
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its sub/daughter clones. Hybridomas and Vγ9Vδ2 TCR transductant were co-cultured along with HMBPP 
(with/without BTN3 103.2 antibody) overnight. Jurkat hCD80 and BW cells were positive and negative control, 
respectively, for the experiment.  
 
3.2.7 Human chromosome 6 is sufficient for presentation of HMBPP and zoledronate 
mediated PAg  
Though our data on human/mouse hybrids supports the necessity of chromosome 6 in PAg 
presentation, the sufficiency of chromosome 6 to present endogenous antigen remained an 
open question. Hence, we attempted to evaluate whether chromosome 6 is sufficient for 
presentation of exogenous and endogenous PAg. Therefore, the hybridomas were co-cultured 
with alkylamine (Sec-butylamine; SBA), which was well known as a stimulator of Vγ9Vδ2 T 
cell activation by inhibiting mevalonate pathway (55, 106). Chromosome 6
 
positive clones 
were tested for their ability to activate Vγ9Vδ2 TCR transductants in presence of HMBPP 
and SBA and we found that some clones were unable to activate Vγ9Vδ2 TCR transductants 
in the presence of SBA (Fig 23). To examine whether those SBA non-responsive clones are 
limited to present exogenous antigen (HMBPP) only, we tested those clones for their capacity 
to activate TCR transductants in presence of aminobisphosphonates (Zoledronate; Zol). 
Interestingly, all those SBA non-responsive clones stimulated Vγ9Vδ2 TCR transductants in 
the presence of zoledronate (Fig 23b). The above data suggested that these two classes of 
stimulators, aminobisphosphonates and alkylamines, exert control over mevalonate pathway 
by inhibiting FPPS through different pathway/mechanisms and it doesn’t seem to act via a 
common mechanism as per present knowledge (55). Moreover, the results clearly indicated 
that chromosome 6 is essential for the presentation of endogenous antigen, which was 
accumulated upon aminobisphosphonate treatment. Probable reason behind the lack of SBA 
mediated response could be extinction of activity of some gene(s) involved in SBA mediated 
PAg presentation, because somatic hybrids were known for extinction/loss of gene activity 
(72) and it might also be due to the nature of genetic complexity of mouse/human hybrids. 
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Figure 23: Chromosome 6 positive clones lack SBA mediated PAg presentation  
a) Analysis of Jurkat/BW hybridomas for their ability to activate Vγ9Vδ2 TCR transductant in presence of 
HMBPP (1μM) and SBA (8mM). b) Analysis of SBA non-responsive clones for ability to activate Vγ9Vδ2 
TCR transductant  in the presence of Zol (100 μM). RAJI and BW cells act as positive and negative controls for 
both experiments, respectively. 
 
Figure 24: Characterization of CHO-Chr6 somatic hybrid  
CHO-Chr6 hybrid was characterized for the presence of human chromosome 6 by comparative genomic 
hybridization of CHO Chr 6 with CHO cells using affimetrix GenomeWide SNP6.0 microarrays. Analysis was 
performed by Dr. Claus Jürgen Scholz.  
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Though chromosome 6 seems to be essential for PAg presentation, the involvement of other 
chromosomes in PAg presentation cannot be overruled by the above data because 
chromosome 6 positive clones carry other chromosomes as well. In order to test the 
sufficiency of chromosome 6 to present exogenous and endogenous antigen, we ought to find 
genetically simple and stable cell line. Therefore, we decided to analyze hamster/human 
chromosome 6 somatic hybrid cell line (CHO-chr6 somatic hybrid), which is monosomal for 
human chromosome 6. Hence, this cell line could act as a perfect tool to evaluate the 
sufficiency of chromosome 6 in PAg presentation. CHO-chr6 somatic hybrids were analyzed 
for the presence of chromosome 6 and other human genomic content by chromosomal array 
analysis. The hybrids were positive only for human chromosome 6 and lack the other 
chromosomes (Fig 24). 
 
Figure 25: Chromosome 6 is sufficient for PAg presentation but not alkylamines mediated PAg 
presentation  
CHO-chr 6 somatic hybrid cell line was tested for its ability to present PAg to Vγ9Vδ2 TCR transductant. CHO-
chr6 somatic hybrid cell line and Vγ9Vδ2 TCR transductant were co-cultured along with different concentration 
of HMBPP, SBA and Zol overnight. HMBPP- exogenous PAg; SBA – Sec-butyl amine (alkylamine), Zol- 
Zoledronate (aminobisphosphonate). 
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The stimulation of Vγ9Vδ2 TCR transductants with CHO-chr 6 somatic hybrid in presence of 
exogenous antigen, alkylamine and aminobisphosphonates (HMBPP, SBA and Zol) revealed 
that CHO-chr6 somatic hybrid could activate Vγ9Vδ2 TCR transductants only in presence of 
exogenous PAg and aminobisphosphonate but not in presence of alkylamine (Fig 25). The 
above experiment clearly confirmed that chromosome 6 is sufficient for presentation of 
exogenous PAg and endogenous antigen accumulated due to aminobisphosphonate treatment. 
But still the reason behind the lack of response to SBA remains unclear.  Because of the 
heterogeneous nature of genetic material, there might be the probable inhibition of genes on 
chromosome 6 which are involved in SBA response and it cannot be overlooked. Also the 
possibility for the necessity of genes on other chromosome(s) for successful SBA mediate 
PAg presentation still remains open. Altogether, the above result confirmed that chromosome 
6 is sufficient for presentation of exogenous and endogenous PAg to Vγ9Vδ2 TCR.   
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4. Discussion 
 
4.1 Identification of alpaca and other non-primate candidate species which probably 
conserved Vγ9Vδ2 T cells  
Human γδ T cells constitute around 5 % of the total T cell population in peripheral blood 
(26). In which, a major subset expressing Vγ9Vδ2 TCR makes up 95% of the γδ T cell 
population (44, 45). They recognize pyrophosphate intermediates of the mevalonate pathway 
of isoprenoid synthesis in all vertebrates and most other animals and the MEP pathway of 
plants, many eubacteria and apicomplexaen parasites (49, 50). Such pyrophosphate 
metabolites are called as phosphoantigens (PAg). Vγ9Vδ2 T cells recognizing PAg were 
conserved in higher primates as well but absent in rodents (60, 65, 67). Hence, Vγ9 and Vδ2 
TCR genes and Vγ9Vδ2 T cells were believed to be restricted to primates (107). Vγ9Vδ2 T 
cells recognize PAgs in MHC independent manner, but BTN3A1 is essential for PAg 
mediated activation of Vγ9Vδ2 T cells (66, 68, 71). Though BTN3A1 is mandatory for PAg 
presentation, the exact molecular basis of the PAg presentation is unclear.  
Since Vγ9Vδ2 T cells are absent in classical small animal models such as mice, rat and 
hamster, the study on these cells was so far restricted to primates alone, which has a number 
of limitations (costs, ethical reasons, the availability of research tools). Hence, we aimed at 
identifying other possible non-primate species which could carry phosphoantigen responsive 
Vγ9Vδ2 T cells. To achieve the above, we performed a comprehensive analysis of 
mammalian genomic database (NCBI), in search of species carrying Vγ9 and Vδ2 TCR genes 
and BTN3A1, the gene of the putative antigen presenting molecule. For the first time, our 
study clearly shows that Vγ9, Vδ2 and BTN3 genes emerged and co-evolved along with 
placental mammals because of the absence of these genes in pre-eutherian species such as 
marsupials and monotremeta (data not shown). Both magnorders of placental mammals 
include species carrying all three genes (Fig 5). Thus it is evident that Vγ9, Vδ2 and BTN3 
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genes are not restricted to primates. Secondly, this thesis has provided the first evidence for 
the existence of Vγ9-γ and Vδ2-δ TCR chains as well as BTN3 gene in alpaca, with features 
typical for the PAg responsive Vγ9Vδ2 T cells identified in humans and primates. 
Furthermore, our study has led to identification of at least 5 more candidate species (non-
primates) which could possess Vγ9Vδ2-like T cell population and need to be tested. 
The distribution pattern of functional Vγ9, Vδ2 TCR genes and BTN3 gene among placental 
mammals clearly indicated the functional association between these genes replicating TCR-
ligand relationship. The functional association is obvious from the observation that wherever 
a species carries functional Vγ9 and Vδ2 genes, it carries a functional BTN3 gene as well. 
Secondly, a species which lacks Vγ9 and Vδ2 genes lacks BTN3 gene also. Such a 
distribution pattern clearly suggests that the functional character of Vγ9Vδ2 T cell could be 
presumable under the control of Vγ9, Vδ2 and BTN3 genes.   
The presence of PAg responsive Vγ9Vδ2 T cells have been reported only for higher primates 
(60, 65-67), but search across the mammalian database revealed the presence of in silico 
translatable Vγ9, Vδ2 genes and BTN3 genes in aye-aye and grey mouse lemur. So, it is 
evident that the genes controlling PAg reactive γδ T cell population were conserved 
throughout the primate lineage not only to higher primates (Fig 6 and 9). Interestingly, 
philippine tarsier, member of tarsiiformes (Haplorrhini; higher primate), lacks Vδ2 gene. 
Further analysis of this species is necessary to clarify whether lack of gene is real or due to 
lack of sequence data. The latter implies that conservation of Vγ9Vδ2 T cell in primate 
lineage could be a strategy for the effective immune-surveillance (107). The former will 
represent an exception in primate lineage where one member of the lineage has lost the PAg 
responsive T cell population. This would probably widen the arena to investigate for the 
possible mechanism or population to compensate the absence of Vγ9Vδ2 T cell population in 
primates. 
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In contrast to primates, small animal models such as mice and rat were known for the 
common absence of Vγ9, Vδ2 TCR genes (19) and they lack BTN3, but possess a similar 
homologue called Skint which is not associated to PAg response. Moreover, the above 
knowledge fits well with lack of reports on PAg reactive T cells from rodents and they are 
believed to lack PAg responsive Vγ9Vδ2 T cell system. However, analysis of public domain 
database revealed an interesting data, where Spermophilus tridecemlineatus (Thirteen lined 
ground squirrel); a lone member of rodent family was identified to possess functional genes 
homologous to Vγ9 and BTN3 genes. But we could not identify a homologue for Vδ2 gene 
from database. It will be interesting and compelling to investigate whether the lack of 
homologue for Vδ2 gene is due to incomplete database sequence or nature of the organism 
itself. The former would lead to identification of a first small animal model which can be 
tested for the presence of Vγ9Vδ2 T cells and will be an exception in the rodent order. In 
depth investigation of such an organism could be an interesting model to understand the 
possible physiological reasoning behind the preservation of Vγ9Vδ2 T cells and for possible 
physiological consequences of PAg responsive Vγ9Vδ2 T cells system as compared with 
species from other rodent families.  
Besides primates, Vγ9 and Vδ2 genes have been identified in several non-primate species but 
they were lost or remain non-functional in many species as well. Interestingly, compared to 
Vδ2, Vγ9 gene is relatively more conserved, even in phylogenetically distinct species (human 
and sloth). The nature of conservation of Vγ9 gene indirectly suggests the existence of 
evolutionary pressure to retain the quality of sequence which might be necessary for the 
preservation of its functional property. Despite the fact, among TCR genes Vγ genes are very 
diverse which was exclusively shown by the presence of unique Vγ genes in mouse and 
human (19). Furthermore, compared to Vγ9, Vδ2 gene has been preserved relatively by more 
species, which raises the possibility for compensation of function of Vγ9 gene by other 
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antigen recognition receptor genes or that function of Vγ9Vδ2 T cells could be dispensable in 
those species.  
Such a differential distribution pattern reminds of another distinct innate T cell population, 
‘iNKT’ cells, which recognizes antigen presented by CD1d. With regard to CD1, there exists 
five distinct CD1 isoforms in human, whereas rodents bear only CD1d (108). Moreover, 
innate like T cell population can have a different physiological role in different species, even 
if they hold a highly conserved genetic organization which is very well demonstrated in 
iNKT cells. Though iNKT TCR genes and antigen presenting molecules were highly 
conserved between humans and rodents, dramatic difference in frequency in CD1d restricted 
iNKT population was observed between human, rat and mice (109). A similar scenario was 
recorded for another conserved innate T cells, subset ‘MAIT’ cells which are restricted to 
MR1 molecule (110).  
However, differential pattern of Vγ9Vδ2 T cell, which is indirectly reflected by the 
distribution pattern of Vγ9, Vδ2 genes and BTN3 genes, could be an illustrative example of 
the differential dynamics of evolution for an innate T cell population within different 
phylogenetic groups. Importantly, it is necessary to identify the presence of distinct Vγ9Vδ2 
T cell population in every candidate species in-order to understand the physiological 
importance of conservation of such T cell population in a few distinct species. 
Though Vγ9, Vδ2 and BTN3, genes were distributed across placental mammals only few non-
primate species namely alpaca, armadillo, sloth, bottle-nose dolphin, killer whales, wild 
Bactrian camel and horse carry in silico translatable genes. With exception of horse, these 
species possess functional genes, whereas in case of horse its Vγ9 and Vδ2 genes carry Ig-
domain disturbing mutations where conserved cysteine residues were replaced as per NCBI 
database sequence. The quality of database sequence was validated by sequence analysis of 
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genomic DNA of horse PBMC. The failure to amplify Vγ9 and Vδ2 TCR chains from cDNA 
of horse PBMC further strengthened the likely absence of Vγ9Vδ2 T cell population in horse 
(M.M.K unpublished data). Interestingly, as per NCBI database sequence, cow carries 
homologous sequence for Vγ9, Vδ2 and BTN3 genes but it carries stop codons in Vγ9 and 
BTN3 in silico translatable sequences. Analysis of genomic DNA sequence of cow confirmed 
the presence of stop codons in Vγ9 like genomic sequence (unpublished data) (Fig 7), which 
explains the reason for the absence of Vγ9 containing transcripts in circulating bovine γδ T 
cells (111). This apparently raises question over the mechanism of phosphoantigen 
responsive γδ T cells in cow (112). But it does not exclude the possibility of presence of T 
cell population which can confer functions analogous to Vγ9Vδ2 T cell, though it demands a 
formal demonstration for cognate recognition of PAg by γδ TCR in the cow. 
Analysis of alpaca PBMC revealed the presence of Vγ9 and Vδ2 TCR chains with the 
features typical for PAg responsive Vγ9Vδ2 T cells. Those features are: 1) Presence of Vγ9 
with preferential recombination to JP segment indicating a strong selection for Vγ9JP 
rearrangement, 2) Partial conservation of germ line encoded lysine residues (K1-K3) in JP, 3) 
Diversity in length exhibited by CDR3δ sequences, and restriction in diversity of length by 
±2 in CDR3γ and the 4) Presence of aliphatic hydrocarbon residues such as glycine, 
isoleucine, leucine and valine at δ97 position of alpaca Vδ2-δ TCR chains. Moreover, 
successful surface expression of alpaca Vγ9Vδ2 TCR chains in αβ TCR negative BW 
thymoma cells, followed by IL-2 production by alpaca TCR transductants upon CD3 
crosslinking clearly indicated the functional nature of alpaca Vγ9Vδ2 TCR. Interestingly, two 
distinct species human and alpaca exhibited compatibility between their TCR chains. Human 
and alpaca Vγ9Vδ2 TCR chains co-transduced BW thymoma cells have shown the surface 
expression of human alpaca chimeric Vγ9Vδ2 TCR. Interestingly, human Vγ9 chains pairs 
with alpaca Vδ2 chain to form a functional TCR but somehow for unknown reasons alpaca 
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Vγ9 chains did not pair up with human Vδ2 chains (data not shown). When alpaca TCR 
transductants were tested for PAg response in presence of RAJI as presenters, they failed to 
respond to the antigen. But this might be due to species specific barriers. In future, the 
response of alpaca Vγ9Vδ2 TCR transductants towards PAg can be tested by using rat CD80 
and alpaca BTN3 transduced alpaca or camelid origin cells lines as antigen presenters, which 
could provide insights on antigen recognition properties of alpaca TCRs. Also for further 
investigation of alpaca Vγ9Vδ2 T cells, it is necessary to generate necessary reagents and 
antibodies. These TCR transductants will also be powerful tools for generation of monoclonal 
antibodies where they can serve as antigen and can be used for the screening of hybridoma 
producing γδ TCR specific antibodies. Finally, they can be used as a tool to screen and 
investigate the properties of in-vivo Vγ9Vδ2 T cell population of alpaca.  
In the recent past, it has been well documented that BTN3A1 is an inevitable associate for the 
PAg mediated and PAg independent activation of Vγ9Vδ2 T cells by human and primates 
(66, 68, 71). Identification of BTN3 gene was mandatory to strengthen the arguable presence 
of Vγ9Vδ2 T cells in alpaca. Due to lack of complete BTN3 gene sequence, full length BTN3 
sequence was identified by the 5’ RACE PCR analysis. The predicted PAg binding residues 
of human BTN3A1 were 100% conserved in deduced amino acid sequence of alpaca BTN3 
(Fig 15). Furthermore, very recent work from Andrew et al. has demonstrated the binding of 
PAg to basic residues at intracellular B30.2 domain of human BTN3A1 (113). To our 
surprise, all those predicted residues are conserved 100% in alpaca BTN3 as well (data not 
shown). In overall, on the basis of features preserved by alpaca Vγ9, Vδ2 TCR chains and 
BTN3 gene, alpaca could be a promising non-primate species preserving Vγ9Vδ2 T cells. 
Therefore, we took an attempt to perform preliminary experiment to test alpaca PBMC with 
agonist anti-BTN3 and HMBPP. Interestingly, alpaca PBMC treated with agonist anti-BTN3 
has shown the activation of PBMC but not in case of PAg treated cells. The above 
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observation, led to the interpretation for the possible existence of PAg independent activation 
of Vγ9Vδ2 T cells, as PAg independent BTN3 mediated activation of Vγ9Vδ2 T cells was 
well established (66, 68). Innate γδ T cells are an established system for recognition of stress 
related ligands as a mechanism of stress surveillance (42, 62). So our observation could well 
support the possible mechanism of BTN3 being recognized as a ligand by alpaca Vγ9Vδ2 T 
cells. Additionally, lack of response to PAg by alpaca PBMC indirectly favors the above 
hypothesis. However, it is hard to derive a conclusion on functional properties of alpaca 
Vγ9Vδ2 T cells based on our observation from our preliminary experiment. It is necessary to 
generate reagents mentioned elsewhere in text, to identify distinct Vγ9Vδ2 T cell population 
of alpaca to assess their response toward PAg and to understand the physiological 
significance of these T cells in alpaca.  
In conclusion, we report that Vγ9, Vδ2 genes and BTN3 emerged and co-evolved along with 
placental mammals. Furthermore, we provide data for the likely presence of Vγ9Vδ2 like T 
cells in alpaca and suggest alpaca as promising non-primate model to investigate the 
functional properties and antigen recognition properties of such a population. In-depth 
studies, addressing these cells are expected to pave way for understanding the functional 
aspects of Vγ9Vδ2 T cells in different physiological models and may even lead to the 
development therapeutic strategies based on Vγ9Vδ2 T cells. 
4.2 Somatic hypermutation in camelids? An open question. 
An interesting facet of the analysis of alpaca TCR γ and δ chains was the search for somatic 
hypermutation (SHM) and the absence of SHM in Vγ9 and Vδ2 chains of alpaca. 
Interestingly, such mutations have been reported for V regions of non-Vγ9 and non-Vδ2 like 
genes in another camelid, the dromedary (97, 98). Since alpaca is phylogenetically related to 
camel family, we analyzed for the presence of SHM in those V genes which were reported 
earlier for SHM in dromedary. Analysis of those V genes for SHM revealed accumulation of 
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mutations at moderate frequency at CDR1 and CDR2 regions, and very sparse mutations in 
the framework regions of TRDV1 and TRDV4 genes but not other V genes. The frequency of 
mutations observed in TRDV1 and TRDV4 of the alpaca was far less than that of a 
dromedary. Moreover, analysis of alpaca genomic database revealed the presence of several 
genomic homologues (at least 3 homologues) for those V genes which possess 
variations/mutations at CDR1 and 2, and at framework regions with similar frequency. It 
indicates the presence of several duplication events in alpaca for those V genes at least. 
Though our study suggests the possible presence of SHM in TRDV1 and TRDV4 of alpaca, it 
still requires in depth analysis to validate them as well as to make sure that they are not 
representation of duplication events. Further investigation in future might involve 
amplification and sequencing of complete TCRG and TCRD locus, followed by analysis of a 
larger cohort of cDNA clones carrying these genes for identification of V genes with SHM 
and to measure the load of mutations at framework regions and CDRs. As a result, two 
possible outcomes can be expected. One could be the lack of SHM and variation observed in 
clones could have been due to massively duplicated genes. This is quite possible because 
ruminants were proven to possess enormous duplication events in γ and δ TCR locus (99-
101). Possible reasons for the divergent results could be differences between species in 
general. Second is an interesting possibility that γδ TCR bearing certain V genes undergo 
SHM and others do not. In this the case numerous questions arise; such as differential 
accessibility of gene loci to SHM or whether variable SHM might reflect divergent lifestyle 
or function of the γδ T cell subpopulation. Hence, investigation for SHM in alpaca V genes 
might yield better understanding towards the role of SHM in TCR genes specifically in 
limited species.  
Another interesting data on dromedary was identification of homologue for Vγ9 gene. Earlier 
analysis of gamma and delta locus of dromedary resulted in non-identification of Vγ9 and 
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Vδ2 genes (97, 98). But from the available genomic sequence of dromedary, we could 
identify functional homologue for Vγ9 gene but not Vδ2. We speculate that absence of Vδ2 
gene sequence could be merely due to incomplete database sequence. Also the presence of 
orthologous sequences to BTN3 raises the probability for the presence of functional Vδ2 like 
gene sequence which might very well fit the conservation of Vγ9Vδ2 TCR-ligand 
relationship. Therefore, analysis of dromedary PBMC would certainly reveal the true nature 
of dromedary with regard to the conservation of such a relationship.  
 
4.3 V9V2 TCR in African green monkey 
Our analysis of African green monkey (AGM; Chlorocebus aethiops) for its ability to present 
PAg to human Vγ9Vδ2 T cells indicated the absence of any barrier to mediate inter-species 
presentation and activation. Though several higher primates were tested for PAg response, 
their ability to cross-present antigen to human Vγ9Vδ2 T cells was sparsely tested. From our 
study, we confirmed the presence of PAg responsive Vγ9Vδ2 T cells in AGM whose 
sequences were earlier unknown (60). Interestingly, germline encoded lysine residues of 
human CDR3γ were partially conserved in AGM, where K1 was replaced by arginine (Fig 
16). Notably, such a substitution was reported earlier in rhesus monkey and was observed in 
alpaca as well (67). Moreover, AGM Vγ9Vδ2 TCR transductants were activated by COS 
rCD80 cells as well as by human RAJI cells in presence of PAg, and the activation was 
increased by several folds in human BTN3A1 transduced COS rCD80 cells (Fig 17). 
However AGM Vγ9Vδ2 transductants can be activated by human RAJI cells even in the 
absence of PAg, which could be due to reactivity to some unknown surface molecules. It will 
be interesting to understand whether the activation of AGM Vγ9Vδ2 TCR transductants is 
mediated by TCR-BTN3 ligand interaction, probably by testing whether this activation can 
be inhibited by BTN3 specific antagonistic antibodies or knock down. Interestingly, human 
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Vγ9Vδ2 TCR transductants also responded to the COS rCD80 and the response was 
enhanced several folds by COS rCD80-hu BTN3 cells. These results clearly indicate the 
absence of any such species barrier which could prevent the activation of human Vγ9Vδ2 
TCRs by COS cells, which was in contradiction to the inability of COS cells to 
activate/stimulate human Vγ9Vδ2 TCR as reported earlier (96). 
 
4.4 Chromosome 6 is sufficient for the presentation of PAg not for activation by 
alkylamines 
The second part of this thesis directly demonstrates that chromosome 6 is a mandatory 
element which carries the essential genes necessary for the presentation of PAg. Also, our 
data indirectly exemplified the advantage of using human-mouse somatic hybrids to map the 
chromosome which confers the functional phenotype. The capacity of Jurkat/BW hybrids to 
activate human Vγ9Vδ2 TCR transductants has directly suggested that genes and molecules 
are specifically involved in PAg presentation system were not disturbed or deregulated by 
genetic nature of somatic hybrids. Characterization of human genomic content in such human 
hybrids, precisely by PCR karyotyping with the use of human chromosome specific primers, 
had a great advantage in such gene/chromosome mapping studies. Such karyotyping tool has 
enabled us to predict the functional phenotype of chromosome 6 by correlating the loss of 
chromosome with loss of capacity of hybrids to activate TCR transductants (Fig 21). 
Eventually analysis of CHO-human chromosome 6 somatic hybrid has confirmed the fact that 
human chromosome 6 is sufficient for the presentation of PAg by antigen presenting cells.  
Screening of Jurkat/BW hybridomas for their capacity to activate Vγ9Vδ2 TCR transductants 
were assessed in presence of HMBPP and SBA (alkylamine) where HMBPP represents 
exogenous PAg presentation and alkylamines accumulates endogenous IPP, which results in 
presentation of endogenous PAg. Initial screening of hybrids indirectly suggested that 
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different chromosomes might be involved in executing exogenous and endogenous PAg 
presentation. We interpret so because the hybrids were able to activate human Vγ9Vδ2 TCR 
transductants in the presence of exogenous PAg, but not in the presence of endogenous PAg 
(Fig 19). Since the hybrids have already lost a few chromosomes, it led to a speculation that 
may be genes involved in SBA mediated response might have been associated with lost 
chromosomes. It was reinforced by analysis of chromosome 6 positive clones that human 
Vγ9Vδ2 TCR transductants are activated in the presence of HMBPP, alkylamine (SBA) and 
aminobisphosphonate (Zol). This revealed that some clones were able to activate TCR 
transductants in presence of HMBPP and Zol but not in the presence of SBA (Fig 23). 
Unfortunately, we were not able to correlate the loss of SBA mediated response with any 
particular chromosome as we could not find out the significant difference in human 
chromosome content between presenting and non-presenting hybrids (data not shown). Since 
human/mouse somatic hybrids were earlier reported for their extinction nature of certain 
tissue specific genes (72), the nature of hybrids could also be a reason behind the specific 
inability to activate TCR transductants in the presence of the SBA. The above finding clearly 
indicates the possible existence of different mechanisms for aminobisphosphonate and 
alkylamine mediated control over IPP consumption or exerting inhibition of IPP consuming 
enzyme FPPS. Finally, analysis of CHO-chromosome 6 somatic hybrid confirmed that 
chromosome 6 is essential and sufficient for the presentation of exogenous and endogenous 
PAg. But still, CHO-Chr 6 somatic hybrid also lacked capacity to activate Vγ9Vδ2 TCR in 
presence of SBA, which could be due to heterogenetic nature of the hybrid. However, the 
observation strengthens the speculation of existence of different cellular mechanism for 
different stimulators to mediate PAg accumulation. At the same time, the probable 
involvement of other genes from other chromosome(s) engaged in SBA mediated response 
cannot be excluded.  
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4.5 Future perspectives 
From our data, we show that Vγ9, Vδ2 and BTN3 genes are not restricted only to primates. 
Secondly, at least 6 non-primate species were identified as candidate species which could 
harbor Vγ9Vδ2 T cell population. Particularly analysis of alpaca has certainly yielded 
promising results and findings that very well support the likely existence of Vγ9Vδ2 T cell 
population. As a next step, it is worth to make an attempt to we hypothesize to amplify Vγ9 
and Vδ2 TCR chains from alpaca PBMC expressing natural Vγ9Vδ2 TCR by using 
techniques such as emulsion PCR. Further, generation of specific reagents like antibodies 
specific for alpaca Vγ9Vδ2 TCR specific antibodies will certainly pave way for the 
identification of distinct Vγ9Vδ2 T cell population.  
Meanwhile, we are taking attempts to characterize alpaca BTN3 for its ability to present PAg 
to alpaca TCR transductants. Since alpaca BTN3 in silico amino acid sequence has conserved 
the predicted PAg binding amino acid, it is worth to express alpaca BTN3 with specific 
knockdown of human BTN3 expression. Interestingly, expression of alpaca BTN3 in a rodent 
background would enable us to investigate PAg independent BTN3 mediate activation of 
alpaca TCR transductants, as we observed the activation of alpaca PBMC co-cultured with 
agonist mAb 20.1 in our preliminary experiments. Additionally, expression of alpaca BTN3 
could pave way to generate antibodies to unravel more about the physiological role of BTN3 
in alpaca. Because, the Skint-1; a closest homologue of BTN3 in mice has been reported for 
playing a significant role in the selection and development of thymic γδ T cells in mice (114, 
115). 
The armadillo is another prime candidate among those which carry functional Vγ9, Vδ2 and 
BTN3 genes owing to the high similarity towards human Vγ9 and Vδ2 genes despite distant 
phylogenetic relationship. Most importantly, an armadillo is a well established model 
organism for Mycobacterium leprae studies since it is being a natural host for the intracellular 
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microbe (116, 117). Moreover, Vγ9Vδ2 T cells are particularly effective against intracellular 
microbe infections (64). It is highly demanding to investigate this species in detail which 
would unravel more about the functional significance and modulations in antigen recognition 
by such T cells. Furthermore, analysis of distinct non-primate species will enable us to 
understand about possible physiological and environmental fundamentals which drive the 
preservation of Vγ9Vδ2 T cells. 
With regard to identification of locus on chromosome 6 involved in PAg presentation, we are 
planning to construct radiation hybrids based on CHO-chromosome 6 somatic hybrid. 
Radiation hybrid could be a useful tool to screen for locus which could carry the genes 
necessary for PAg presentation (118). Moreover, recent results generated from our lab clearly 
indicated that BTN3A1 alone is not sufficient for the PAg mediated activation of Vγ9Vδ2 T 
cells (F.R.A, M.M.K…. T.H unpublished data). In addition, other recent works, though did 
not directly demonstrate the insufficiency of BTN3A1 alone in PAg presentation but still 
supported the fact that other molecules could be involved along with BTN3A1 in presentation 
of PAg (66, 113). Moreover, a recent publication from Andrew et al. demonstrated the 
binding of PAg to intracellular domain of BTN3A1 and the need of other molecules for the 
transport of PAg to the cell surface was ascertained (113). Hence, it is clear that others 
genes/locus on chromosome 6 in association with BTN3A1 is essential for the PAg mediated 
activation of Vγ9Vδ2 T cells.  
Furthermore, the lack of capacity of CHO-chromosome 6 somatic hybrid to activate Vγ9Vδ2 
TCR transductants in presence of SBA made it compelling to investigate SBA mediated 
activation of Vγ9Vδ2 TCR by presenting cells of different origin (species) which carry 
human chromosome-6. Such an experimental condition would enable us to validate whether 
the lack of SBA mediated response is unanimous to all chromosome 6 positive cells. If that is 
not the case, then there should have been some unknown species specific regulators which 
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down-regulate the genes on chromosome 6 that are involved in PAg presentation, which 
eventually led to lack of SBA mediated response. Interestingly, in our lab, we recently 
observed that human skin melanoma cells were unable to activate Vγ9Vδ2 TCR (unpublished 
data) which suggests that the genes involved in PAg could have been down-regulated by 
unknown cellular mechanisms. So it will be interesting to test the capacity of CHO-chr 6 
somatic hybrids to activate Vγ9Vδ2 T cells in the presence of SBA, along with modulators of 
gene expression such as histone deacetylase (HDAC). However, it will be interesting to 
continuously monitor hybrids for loss of chromosomes and probably it can result in 
identification of other chromosome(s) for SBA mediated activation. Such a predicted 
chromosome can be immediately tested by fusing human chromosome specific hamster 
hybrid with CHO-chromosome 6 somatic hybrid, if it results in reconstitution of SBA 
mediated response, then the probable chromosome(s) involved in PAg presentation can be 
identified.  
Here, our data has yielded new findings in the field of Vγ9Vδ2 T cells which we believe 
would open a new perspective towards the evolution of Vγ9Vδ2 T cells, as well new insights 
with regard to molecular mechanism of PAg presentation to Vγ9Vδ2 T cells which are: 1) 
Vγ9, Vδ2 and BTN3 genes emerged and co-evolved along with evolution of placental 
mammals and these genes are not restricted only to primates, 2) identification of alpaca as a 
promising non-primate species to harbor Vγ9Vδ2 T cell population as Vγ9, Vδ2 TCR chains 
and BTN3 carry features typical for PAg reactive Vγ9Vδ2 T cells, 3) human chromosome 6 is 
sufficient for the presentation of exogenous antigen and zoledronate mediated but not for 
SBA mediated PAg presentation. These findings will pave way in understanding the 
modalities of Vγ9Vδ2 T cell activation and immune function, as well as to dissect the 
molecular mechanism involved in PAg presentation to these T cells.  
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AGM African green monkey 
APC Antigen presenting cell 
BrHPP Phosphorylated bromohydrin 
BSA Bovine serum albumin 
BTN3 Butyrophylin 3 
BTN3-ED Butyrophylin 3- extracellular domain 
CD  Cluster of differentiation 
CDR  Complementary determining region 
cDNA Complementary DNA 
CHO Chinese hamster ovary cell  
Chr6 Chromosome 6 
CMV Cytomegalovirus 
DEPC Diethylpyrocarbonate 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
EDTA Ethylendiamintetracetic acid 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
FITC Fluoresceinisothiocyanate 
FPPS Farnesyl pyrophosphate synthase 
GFP Green fluorescent protein 
h Hour 
HAT Hypozanthine, Aminopterin, Thymidine 
HMBPP (E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate 
HT Hypozanthine - Thymidine 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
IPP Isopentenyl pyrophosphate 
iNKT Invariant Natural Killer T cells 
M Molar 
 Abbreviation 
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mAb Monoclonal antibody 
MEP 2-C-methyl-D-erythritol 4-phosphate pathway 
MHC Major histocompatibility complex 
MICA/B MHC class I chain-related gene A/B 
min Minutes 
mRNA Messenger RNA 
PBL Peripheral blood lymphocytes 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PEG Polyethyleneglycol 
RACE Rapid amplification of cDNA ends 
RNA Ribonucleic acid 
RNAase Ribonuclease 
RT Room temperature 
SBA Sec-butylamine 
SiRNA Short interfering RNAs 
TCR T cell receptor 
Tdt Terminal deoxynucleotidyl transferase 
TNF Tumor necrosis factor 
TRIS N, n, n', n'-tetramethylethylenediamine 
ULBPs UL16-binding proteins 
VDJ Variable, Diversity and Joining segments of the TCR chain 
Vp Vicugna pacos 
YFP Yellow fluorescent protein 
Zol Zoledronate 
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